

**LOCAL ANTIMICROBIAL RESISTANCE PATTERN DOCUMENT
(JANUARY-DECEMBER 2023)**

EDITORIAL BOARD

**Chairman: Dr. Shukla Das, Director Professor & Head
Chief-Editor: Dr. Nisha Goyal, Associate Professor (WHONET incharge)**

Members

**Dr. Seema Gangar, Senior Resident (WHONET incharge)
Dr.Dibyashree, Senior Resident**

DEPARTMENT OF MICROBIOLOGY, UCMS & GTB HOSPITAL, DELHI

INDEX

S.NO	TITLE	PAGE NO
1	AST OF PATHOGENS FROM UCMS & GTB HOSPITAL	4
2	AST OF PUS PATHOGENS	7
3	AST OF RESPIRATORY PATHOGENS	14
4	AST OF BODY FLUIDS (EXCEPT CSF) PATHOGENS	20
5	AST OF BLOOD PATHOGENS	24
6	AST OF URINARY PATHOGENS	31
7	AST OF CSF PATHOGENS	38
8	AST OF ENTERIC PATHOGENS	42
9	AST OF PATHOGENS ISOLATED FROM MEDICINE DEPARTMENT	46
10	AST OF PATHOGENS ISOLATED FROM SURGERY DEPARTMENT	52
11	AST OF PATHOGENS ISOLATED FROM PEDIATRICS DEPARTMENT	58
12	AST OF PATHOGENS ISOLATED FROM ORTHOPAEDICS DEPARTMENT	64
13	AST OF PATHOGENS ISOLATED FROM OPHTHALOMOLOGY DEPARTMENT	70
14	AST OF PATHOGENS ISOLATED FROM ENT DEPARTMENT	74
15	AST OF PATHOGENS ISOLATED FROM DERMATOLOGY DEPARTMENT	78
16	AST OF PATHOGENS ISOLATED FROM OBSTRETICS & GYNAECOLOGY DEPARTMENT	82

DISCLAIMER: This document is purely for Educational Purpose and for Internal Circulation in UCMS & GTB Hospital, Delhi Only. No parts/parts shall fully/partially be copied, plagiarized, imitated, published or reproduced anyway whatsoever, without prior permission from the Chairman of the Editorial Board




DEPARTMENT OF MICROBIOLOGY, UCMS & GTB HOSPITAL, DELHI

AST	ANTIMICROBIAL SUSCEPTIBILITY PATTERN (AST)
MRSA	Methicillin-resistant Staphylococcus aureus
MSSA	Methicillin-Sensitive Staphylococcus aureus
IR	Intrinsic resistant
NT	Not tested
NBP	No breakpoint available

Colouring Scheme used	
	Susceptibility % > 80%
	Susceptibility % = 60-80%
	Susceptibility % <60%
	Data not available (includes IR, NT,NBP)

**ANTIMICROBIAL SUSCEPTIBILITY
PATTERN OF UCMS & GTB
HOSPITAL
(YEAR 2023)**

Distribution of bacterial isolates from GTB hospital in the year 2023



**SAMPLE WISE
ANTIMICROBIAL
SUSCEPTIBILITY PATTERN**

**ANTIBIOTIC SUSCEPTIBILITY OF
PUS PATHOGENS
(JAN – DEC 2023)**

Antimicrobial susceptibility pattern for gram positive bacterial isolates from pus specimen

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin% (n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin %(n)	Tetracycline%(n)	Gentamicin%(n)	High level Gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)
<i>Staphylococcus aureus</i>	OPD	820	26.8 (485)	70.7 (147)	62.3 (735)	22.1 (804)	98 (49)	NBP	61.5 (600)	65.7 (105)	NBP	89.8 (245)	8.6 (187)
	IPD	704	28.5 (354)	65.5 (84)	58.1 (532)	22.8 (694)	97 (313)	NBP	0(2)	72.3(65)	NBP	NT	9 (234)
	ICU	20	13.3 (15)	40 (5)	78.9 (19)	45 (20)	87.5 (8)	NBP	69.2 (13)	66.7 (3)	NBP	NT	0 (2)
<i>MRSA</i>	OPD	355	0(355)	55.3(38)	55.7 (350)	16.8 (351)	97.3 (184)	NBP	48.5(274)	59.7(67)	NBP	86(36)	6.1(49)
	IPD	241	0(241)	56(25)	49.2(36)	17.7 (237)	95.7 (115)	NBP	45.5(189)	70.7(41)	NBP	84.5(58)	2.7(37)
	ICU	11	0(11)	50(2)	72.7(11)	27.3(11)	83.3 (6)	NBP	57.1(7)	NT	NBP	0(1)	0(1)
<i>MSSA</i>	OPD	136	100(136)	100(2)	72.5 (131)	31(129)	98.4 (75)	NBP	73.4(94)	82.6(23)	NBP	89.2(37)	11.1(18)
	IPD	98	100(98)	33.3(3)	70.7 (92)	31.6 (95)	100 (37)	NBP	65.7(67)	80(10)	NBP	81.3(32)	12.5(8)
	ICU	2	100(2)	NT	100(2)	100(2)	100 (1)	NBP	100(1)	NT	NBP	100(1)	NT

Gram Positive Cocci	Location	Isolates (n)	Cefoxitin% (n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin %(n)	Tetracycline%(n)	Gentamicin%(n)	High level Gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)
CONS	OPD	170	26.1(88)	45.5(22)	55.8(154)	18.9(164)	96.6(58)	NBP	50.8(128)	70.6(17)	NBP	76(50)	16.7(30)
	IPD	180	7.6(79)	45(20)	44.4(135)	23(174)	94.9(99)	NBP	63.5(115)	63.2(19)	NBP	86.5(52)	31.9(47)
	ICU	21	NT	NT	NT	NT	NT	NBP	NT	0(13)	NBP	0(1)	9.1(11)
<i>Enterococcus faecalis</i>	OPD	16	IR	IR	IR	12.5(8)	75(4)	75(8)	NBP	IR	90(10)	75(4)	NBP
	IPD	36	IR	IR	IR	5(19)	76(17)	66(12)	NBP	IR	64(28)	83(18)	NBP
	ICU	1	IR	IR	IR	NT	0(1)	NT	NBP	IR	0(1)	NT	NBP
<i>Enterococcus faecium</i>	OPD	3	IR	IR	IR	0(1)	100(1)	100(1)	NBP	IR	100(2)	100(1)	NBP
	IPD	8	IR	IR	IR	0(7)	86(7)	100(2)	NBP	IR	26(7)	66(6)	NBP
<i>Enterococcus spp.</i>	OPD	29	IR	IR	IR	38.9(15)	90.4(12)	54.5(12)	NBP	IR	80(21)	95.2(11)	NBP
	IPD	76	IR	IR	IR	3.4(48)	95.2(38)	43.8(20)	NBP	IR	67.8(59)	75.2(45)	NBP
	ICU	24	IR	IR	IR	0(1)	66.6(3)	NT	NBP	IR	33.3(3)	0(1)	NBP
<i>Streptococcus pneumoniae</i>	OPD	1	NBP	100(1)	100(1)	100(1)	NT	NT	100(1)	NBP	NBP	NT	NBP
	IPD	2	NBP	50(2)	100(1)	50(2)	NT	100(1)	0(1)	NBP	NBP	100(1)	NBP



Antimicrobial susceptibility pattern for gram negative bacterial isolates from pus specimen
 [% of susceptible (total number of isolates tested for a given antibiotic)]=%(n)]

Gram Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Cefotaxime%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Aztreonam%(n)	Imipenem%(n)	Meropenem%(n)
<i>Escherichia coli</i>	OPD	127	13.2(114)	33.3(3)	46.2(78)	7(86)	32(102)	17.6(17)	30(10)	40(10)	49.6(117)	0(1)
	IPD	396	12.6(357)	0(4)	47.6(185)	5.2(271)	21.3(301)	82(69)	19.4(31)	22.7(22)	45.4(350)	66.7(6)
	ICU	7	16.7(6)	NT	33.3(3)	0(5)	20(5)	0(2)	0(2)	0(1)	25(4)	NT
<i>Pseudomonas aeruginosa</i>	OPD	278	IR	IR	NBP	46.9 (175)	79.6(225)	NBP	62.4(250)	67(115)	72(232)	100(1)
	IPD	197	IR	IR	NBP	34.5 (110)	61.4(145)	NBP	59.1(176)	59.5(116)	62.7(158)	100(1)
	ICU	6	IR	IR	NBP	0(5)	33.3(6)	NBP	0(6)	100(2)	20(5)	NT
<i>Acinetobacter baumannii</i>	OPD	72	6.8(59)	0(2)	26.9(52)	22.8(57)	25.4(59)	33.3(9)	14.3(7)	IR	23.5(68)	50(2)
	IPD	324	5.6(234)	0(9)	20.5(116)	11.3 (204)	55(225)	10.5(57)	21.6(37)	IR	12.7(291)	0(2)
	ICU	21	6.3(16)	NT	0(13)	19.1(11)	0(14)	0(4)	0(2)	IR	0(16)	0(1)

Gram Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Cefotaxime%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Aztreonam%(n)	Imipenem%(n)	Meropenem%(n)
<i>Klebsiella pneumoniae</i>	OPD	119	39.2 (102)	0 (1)	54.7 (64)	36.8 (38)	34.1 (85)	36.8 (38)	50 (16)	33.3 (6)	42.9 (105)	75 (4)
	IPD	276	23.6 (237)	33.3 (3)	36.5 (126)	16.4 (171)	26.4 (216)	26.3 (99)	23.1(39)	42.9(14)	39(249)	66.7 (6)
	ICU	9	0(8)	NT	25(5)	0(5)	14.3(7)	0(1)	100(1)	NT	12.5(8)	NT
<i>Klebsiella oxytoca</i>	OPD	12	33(9)	NT	50(4)	33(4)	62(8)	66(3)	50(4)	100(2)	63(11)	NT
	IPD	9	12(25)	NT	50(14)	9(21)	12(24)	25(8)	25(4)	50(2)	33(24)	0(1)
	ICU	2	50(2)	NT	0(1)	0(1)	100(1)	0(1)	NT	100(1)	100(1)	NT
<i>Enterobacter spp.</i>	OPD	155	22(134)	0(2)	45 (99)	18 (105)	32 (130)	42(31)	0(8)	27(11)	50(135)	33(3)
	IPD	239	3(206)	0(26)	40(132)	9(159)	19(164)	26(57)	14(14)	26(35)	29(203)	33(3)
	ICU	2	0(2)	NT	0(1)	0(1)	0(1)	NT	NT	NT	0(2)	NT
<i>Proteus vulgaris</i>	OPD	7	71(7)	NT	66(3)	33(6)	83(6)	100(2)	NT	NT	50(2)	NT
	IPD	14	28(14)	NT	37(8)	28(7)	57(7)	100(1)	NT	75(4)	0(5)	NT
<i>Proteus mirabilis</i>	OPD	89	55.9(68)	100(1)	50.9(53)	14.9 (67)	67(74)	54.5 (22)	50(6)	83(15)	IR	NT
	IPD	74	45.8(59)	66.7(7)	50(38)	14.3 (56)	63.8(58)	31.3 (16)	22.2(9)	90(10)	IR	100(2)
	ICU	21	NT	NT	0(13)	9.1(11)	0(14)	0(4)	0(2)	0(1)	IR	0(1)

Gram Negative Bacilli	Location	Isolates(n)	Ceftriaxone%(n)	Cefotaxime%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Aztreonam%(n)	Imipenem%(n)	Meropenem%(n)
<i>Citrobacter koseri</i>	OPD	69	36(65)	0(1)	70(52)	22(50)	30(56)	62(8)	NT	33(18)	59(61)	NT
	IPD	87	25(18)	0(2)	58(44)	18(54)	20(65)	33(9)	33(3)	40(32)	35(68)	NT
	ICU	13	12(12)	NT	25(9)	0(9)	7(9)	NT	NT	0(2)	31(12)	NT
<i>Citrobacter freundii</i>	OPD	55	32(43)	33(3)	51(29)	NT	39(46)	34(11)	50(4)	50(2)	56(48)	100(2)
	IPD	86	13(77)	0(3)	43(46)	12(57)	24(66)	31(16)	23(13)	11(9)	32(80)	66(33)
	ICU	1	0(1)	NT	NT	NT	NT	NT	NT	0(1)	NT	NT
<i>Citrobacter spp.</i>	OPD	202	36.5(74)	0(1)	71.2(59)	24.1(58)	31.7(63)	66.7(9)	NT	31.6(19)	58.8(68)	NT
	IPD	295	23.6(110)	0(4)	65.1(63)	15.4(78)	83.9(92)	27.3(11)	20(5)	35.7(42)	49(96)	0(1)
	ICU	28	28.6(7)	NT	16.7(6)	0(6)	0(3)	NT	NT	25(4)	33.3(6)	NT

ANTIBIOTIC SUSCEPTIBILITY OF PUS PATHOGENS JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF
RESPIRATORY PATHOGENS
(JAN – DEC 2023)**

Antimicrobial susceptibility pattern for gram positive bacterial isolates from respiratory specimen

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin%(n)	Tetracycline%(n)	High -Level Gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Gentamicin%(n)
<i>Staphylococcus aureus</i>	OPD	14	83.3 (6)	50(2)	46.2 (13)	21.4 (14)	75(4)	NBP	72.7 (11)	NBP	100(7)	NT	NT
	IPD	43	38 (24)	66.7(3)	41(32)	17.1 (41)	100 (23)	NBP	53.8 (26)	NBP	86.7 (15)	14.3 (14)	100(3)
	ICU	11	0(5)	0(1)	55(6)	30(10)	100(2)	NBP	57(7)	NBP	59(5)	0(3)	0(2)
MRSA	OPD	2	0(2)	NT	0(2)	0(2)	NT	NBP	0(1)	NBP	100(1)	NT	100(2)
	IPD	19	0(19)	100(1)	38.9(18)	11.1(18)	100(5)	NBP	38.5(13)	NBP	100(6)	0(1)	100(2)
	ICU	5	0(5)	NT	60(5)	40(5)	100(1)	NBP	66.7(3)	NBP	100(2)	NT	NT
MSSA	OPD	4	100(4)	NT	100(4)	50(4)	100(1)	NBP	66.7(3)	NBP	100(2)	NT	NT
	IPD	5	100(5)	NT	80(5)	20(5)	100(2)	NBP	66.7(3)	NBP	66.7(3)	NT	NT
	ICU	1	100(1)	NT	NT	NT	NT	NBP	NT	NBP	0(1)	0(1)	0(1)
CONS	OPD	6	20(5)	NT	40(5)	16.7(6)	100(2)	NBP	20(5)	NBP	100(1)	0(2)	NT
	IPD	4	33.3 (3)	NT	100(4)	0(4)	NT	NBP	66.7(3)	NBP	NT	0(1)	0(1)
	ICU	4	100(1)	NT	33.3(3)	33.3(3)	100(2)	NBP	0(2)	NBP	100(1)	0(1)	66.7(3)

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin%(n)	Tetracycline%(n)	High -Level Gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Gentamicin%(n)
<i>Streptococcus spp.</i>	IPD	3	NBP	NBP	100(1)	50(3)	100(1)	100 (2)	0(2)	NBP	100(2)	NBP	NBP
Enterococcus spp.	IPD	2	IR	IR	IR	0(2)	NT	NT	NBP	NT	NT	NBP	IR
	ICU	2	IR	IR	IR	0(1)	100(2)	NT	NBP	0(1)	100(1)	NBP	IR


Antimicrobial susceptibility pattern for gram negative bacterial isolates from respiratory specimen
[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Imipenem%(n)	Ceftazidime%(n)	Aztreonam%(n)	Chloramphenicol%(n)
<i>Klebsiella pneumoniae</i>	OPD	79	68.2 (66)	74.4 (39)	56.8(44)	57.5 (56)	52.9 (17)	44.4 (79)	73.3 (75)	42.9 (14)	80 (5)	83.3(6)
	IPD	88	17.6 (68)	NT	11.1(54)	45.3 (64)	NT	NT	51(3)	20 (10)	25(8)	75 (8)
	ICU	30	4(25)	16.7(12)	0(22)	8(25)	0(10)	28.6(7)	20.8 (24)	0(2)	0(2)	100 (1)
<i>Acinetobacter baumannii</i>	OPD	17	0 (16)	7.1 (14)	0 (16)	11.8 (17)	50 (2)	NT	0 (16)	NT	IR	IR
	IPD	44	5.6 (36)	9.5 (21)	6.1 (33)	13.8 (29)	14.3 (7)	33.3 (3)	5.7 (35)	25(15)	IR	IR
	ICU	107	1.1 (89)	8.9 (45)	2.6 (78)	2.6 (78)	0 (17)	14.3 (7)	2.1 (94)	0 (16)	IR	IR
<i>Pseudomonas aeruginosa</i>	OPD	18	IR	NBP	84.6(13)	100 (12)	NBP	93.3 (15)	86.7 (15)	84.6 (13)	87.5(8)	IR
	IPD	28	IR	NBP	50(16)	71.14 (14)	NBP	82.6 (23)	88.2 (17)	70.8 (20.8)	50(16)	IR
	ICU	15	IR	NBP	50(10)	75 (12)	NBP	57.1 (14)	53.3 (15)	54.5 (11)	75(4)	IR


Gram Negative Bacilli	Location	Isolates(n)	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Imipenem%(n)	Ceftazidime%(n)	Aztreonam%(n)	Chloramphenicol%(n)
<i>Escherichia coli</i>	OPD	6	16.7(6)	20(5)	20(5)	50(6)	50(2)	NT	50(6)	NT	0(1)	100(1)
	IPD	12	100(11)	50(6)	0(7)	10(10)	0(3)	NT	36.4(11)	0(2)	NT	66.7(3)
	ICU	8	0(7)	50(2)	0(3)	0(5)	0(3)	0(2)	20(5)	0(4)	0(1)	NT
<i>Citrobacter koseri</i>	OPD	6	50(6)	80(5)	16.7(6)	66.7(6)	NT	NT	50(6)	NT	33.3(3)	NT
	IPD	7	0(6)	25(4)	0(5)	0(6)	0(1)	NT	51.1(7)	NT	0(2)	NT
	ICU	7	0(2)	20(5)	0(6)	0(5)	0(1)	NT	0(7)	0(2)	NT	NT
<i>Citrobacter freundii</i>	OPD	7	57.1(7)	100(6)	25(4)	100(5)	NT	NT	83.3(6)	NT	100(4)	100(2)
	IPD	8	NT	57.1(7)	28.6(7)	14.3(7)	0(2)	0(1)	37.5(8)	0(2)	33.3(3)	NT
	ICU	2	0(2)	50(2)	0(2)	0(1)	NT	NT	0(2)	NT	0(1)	NT
<i>Citrobacter spp.</i>	OPD	13	53(13)	90(11)	20(10)	83(11)	NT	NT	66(12)	NT	66(7)	100(2)
	IPD	20	0(10)	41(11)	28(12)	14(18)	0(4)	0(1)	44(18)	0(2)	33(5)	100(2)
	ICU	9	0(4)	35(7)	0(8)	0(6)	0(1)	NT	0(9)	0(2)	0(1)	NT

ANTIBIOTIC SUSCEPTIBILITY OF RESPIRATORY PATHOGENS JAN – DEC 2023


AST pattern of *Staphylococcus aureus* isolates from Respiratory specimen



AST pattern of *Klebsiella pneumoniae* isolates from Respiratory specimen



Distribution of Bacterial Isolates from Respiratory Specimen



**ANTIBIOTIC SUSCEPTIBILITY OF
BODY FLUIDS (EXCEPT CSF AND
BLOOD) PATHOGENS
(JAN – DEC 2023)**

Antimicrobial susceptibility pattern for gram positive bacterial isolates from body fluids specimen (except CSF and blood)

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	Isolates(n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin%(n)	Tetracycline%(n)	High Level Gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Gentamicin%(n)
<i>Staphylococcus aureus</i>	OPD	4	NT	0(1)	0(4)	0(4)	100(3)	NBP	66.7(3)	NBP	100(3)	NT	100(1)
	IPD	24	100(1)	100(2)	38.9(18)	20.8(24)	91.7(12)	NBP	50(10)	NBP	87.4(8)	0(5)	100(10)
<i>MRSA</i>	OPD	4	0(4)	0(1)	0(4)	0(4)	100(3)	NBP	67(3)	NBP	100(3)	NT	0(1)
	IPD	9	0(9)	NT	22.2(4)	11.1(9)	100(4)	NBP	50(4)	NBP	100(2)	NT	100(1)
<i>MSSA</i>	IPD	5	100(5)	NT	60(5)	20(5)	100(2)	NBP	0(1)	NBP	100(2)	NT	100(2)
<i>CONS</i>	OPD	1	NT	NT	100(1)	100(1)	100(1)	NBP	NT	NBP	NT	NT	NT
	IPD	13	100(1)	50(2)	60(10)	9.1(11)	100(6)	NBP	57.7(7)	NBP	100(1)	50(2)	0(1)
<i>Enterococcus faecalis</i>	OPD	4	IR	IR	IR	0(1)	100(1)	NT	NBP	NT	100(1)	NBP	IR
	IPD	7	IR	IR	IR	0(1)	100(2)	100(4)	NBP	66.7(6)	100(6)	NBP	IR
<i>Enterococcus faecium</i>	IPD	1	IR	IR	IR	100(1)	100(1)	NT	NBP	100(1)	100(1)	NBP	IR
<i>Enterococcus spp.</i>	OPD	4	IR	IR	IR	0(1)	100(1)	NT	NBP	NT	100(1)	NBP	IR
	IPD	9	IR	IR	IR	50(2)	100(3)	100(4)	NBP	83(7)	100(7)	NBP	IR


Antimicrobial susceptibility pattern for gram negative bacterial isolates from body fluids specimen (except CSF and blood)

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]


Gram Negative Bacilli	Location	Isolates(n)	Ceftriaxone%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Piperacillin-tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Imipenem%(n)	Ceftazidime%(n)	Aztreonam%(n)	Chloramphenicol%(n)
<i>Escherichia coli</i>	OPD	7	0(7)	60 (5)	0 (6)	33 (6)	0(1)	NT	50 (6)	NT	NT	66 (3)
	IPD	54	22 (44)	50 (24)	3 (33)	34 (38)	27 (13)	0 (5)	54 (50)	36 (11)	33 (3)	100(8)
	ICU	7	0(7)	60 (5)	0 (6)	33 (6)	NT	NT	50(6)	NT	NT	66 (3)
<i>Klebsiella pneumoniae</i>	OPD	2	0(2)	0(1)	0(1)	0(2)	NT	NT	0(2)	NT	NT	NT
	IPD	20	57.9(19)	66.7(9)	30(10)	41.2(17)	12.5(8)	0(2)	52.8(19)	50(4)	0(1)	100(3)
	ICU	2	0(2)	0(1)	0(1)	0(2)	NT	NT	0(2)	NT	NT	NT
<i>Acinetobacter baumannii</i>	OPD	3	0(3)	0(3)	0(3)	0(2)	NT	NT	0(2)	NT	IR	IR
	IPD	3	0(3)	0(3)	0(3)	0(2)	NT	NT	0(2)	NT	IR	IR
	ICU	3	0(3)	0(3)	0(3)	0(2)	NT	NT	0(2)	NT	IR	IR
<i>Pseudomonas aeruginosa</i>	OPD	1	IR	NBP	100(1)	100(1)	NBP	100(1)	0(1)	100(1)	NT	IR
	IPD	6	IR	NBP	40(5)	40(5)	NBP	40(5)	40(5)	40(5)	100(2)	IR

ANTIBIOTIC SUSCEPTIBILITY OF BODY FLUIDS (EXCEPT CSF AND BLOOD) PATHOGENS JAN – DEC 2023


AST pattern of Staphylococcus aureus isolates from body fluids (except CSF and Blood) specimen



AST pattern of Escherichia coli isolates from body fluids (except CSF and Blood) specimen



Distribution of bacterial isolates from body fluids (except CSF and Blood) specimen



**ANTIBIOTIC SUSCEPTIBILITY OF
BLOOD PATHOGENS
(JAN – DEC 2023)**

Antimicrobial susceptibility pattern for gram positive bacterial isolates from blood specimen

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	Isolates (n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Linezolid%(n)	Vancomycin%(n)	Tetracycline%(n)	High level gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Gentamicin%(n)	Teicoplanin%(n)
<i>Staphylococcus aureus</i>	OPD	24	60 (10)	33 (9)	59 (22)	30 (23)	100 (9)	NBP	33 (3)	NBP	93 (15)	28 (18)	80 (10)	NBP
	IPD	701	32 (406)	40 (161)	46 (548)	16 (694)	99 (365)	NBP	70 (159)	NBP	85 (270)	38 (538)	60 (274)	NBP
	ICU	219	17 (156)	37 (65)	37 (187)	13 (216)	100 (92)	NBP	43 (46)	NBP	73 (102)	33 (153)	58 (85)	NBP
<i>MRSA</i>	OPD	7	0 (7)	0 (4)	27 (7)	0 (7)	100 (2)	NBP	0 (2)	NBP	100 (5)	0 (4)	67 (3)	NBP
	IPD	289	0 (289)	38 (101)	36 (283)	7 (287)	100 (112)	NBP	51 (45)	NBP	77 (121)	22 (210)	61 (141)	NBP
	ICU	139	0 (139)	33 (54)	25 (137)	7 (139)	100 (50)	NBP	29 (24)	NBP	70 (76)	26 (95)	48 (61)	NBP
<i>MSSA</i>	OPD	11	100 (11)	75 (4)	70 (11)	60 (10)	100 (4)	NBP	NT	NBP	88 (8)	40 (10)	75 (4)	NBP
	IPD	171	100 (171)	49 (47)	60 (167)	30 (171)	98 (77)	NBP	53 (32)	NBP	96 (51)	56 (146)	80 (79)	NBP
	ICU	40	100 (40)	67 (9)	71 (38)	39 (39)	100 (15)	NBP	45 (11)	NBP	92 (13)	52 (29)	83 (18)	NBP

Gram Positive Cocci	Location	Isolates (n)	Cefoxitin%(n)	Cotrimoxazole%(n)	Clindamycin%(n)	Erythromycin%(n)	Lineolid%(n)	Vancomycin%(n)	Tetracycline%(n)	High level gentamicin%(n)	Chloramphenicol%(n)	Ciprofloxacin%(n)	Gentamicin%(n)	Teicoplanin%(n)
CONS	OPD	12	0 (2)	100 (1)	18 (11)	0 (12)	100 (9)	NBP	NT	NBP	89 (9)	30 (10)	100 (2)	NBP
	IPD	254	24 (152)	46 (39)	53 (236)	11 (247)	97 (155)	NBP	64 (63)	NBP	75 (48)	32 (204)	75 (140)	93 (14)
	ICU	242	9 (164)	41 (49)	31 (219)	8 (239)	99 (108)	NBP	34 (61)	NBP	70 (71)	19 (174)	63 (134)	100 (12)
Enterococcus faecalis	OPD	1	IR	IR	IR	0 (1)	100 (1)	NT	NBP	100 (1)	100 (1)	NBP	IR	100 (1)
	IPD	27	IR	IR	IR	5 (21)	93 (14)	72 (7)	NBP	52 (21)	67 (9)	NBP	IR	75 (8)
	ICU	8	IR	IR	IR	29 (7)	67 (3)	33 (3)	NBP	75 (8)	33 (3)	NBP	IR	50 (4)
Enterococcus faecium	IPD	12	IR	IR	IR	20 (10)	100 (3)	17 (6)	NBP	60 (10)	67 (33)	NBP	IR	50 (4)
	ICU	6	IR	IR	IR	25 (4)	100 (4)	67 (3)	NBP	83 (6)	67 (3)	NBP	IR	80 (5)
Enterococcus spp.	OPD	1	IR	IR	IR	0 (1)	100 (1)	NT	NBP	100 (1)	100 (1)	NBP	IR	100 (1)
	IPD	50	IR	IR	IR	17 (35)	98 (16)	52 (16)	NBP	71 (36)	78 (43)	NBP	IR	75 (13)
	ICU	20	IR	IR	IR	18 (13)	89 (11)	33 (6)	NBP	77 (18)	66 (7)	NBP	IR	43 (10)

Antimicrobial susceptibility pattern for gram negative bacterial isolates from blood specimen

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]


Gram Negative Bacilli	Location	Isolates (n)	Tobramycin%(n)	Gentamicin%(n)	Amikacin%(n)	Ceftriaxone%(n)	Piperacillin/tazobactam %(n)	Ciprofloxacin%(n)	Imipenem%(n)	Aztreonam%(n)	Chloramphenicol%(n)	Ceftazidime%(n)
<i>Acinetobacter baumannii</i>	OPD	9	NT	0 (5)	0 (1)	33 (6)	24 (7)	67 (6)	62 (9)	IR	IR	NT
	IPD	187	NT	64 (130)	29 (14)	20 (150)	44 (147)	40 (154)	38 (175)	IR	IR	37 (25)
	ICU	305	NT	33 (220)	0 (33)	13 (245)	30 (254)	38 (222)	16 (267)	IR	IR	6 (47)
<i>Escherichia coli</i>	OPD	14	NT	100 (14)	100 (2)	100 (14)	71 (40)	25 (12)	71 (14)	NT	100 (7)	NT
	IPD	117	NT	92 (106)	70 (10)	73 (108)	74 (114)	23 (104)	79 (110)	58 (12)	85 (28)	29 (7)
	ICU	19	NT	54 (13)	0 (2)	20 (15)	40 (15)	21 (14)	44 (16)	0 (2)	67 (6)	0 (1)
<i>Klebsiella spp.</i>	OPD	3	NT	33 (3)	NT	0 (3)	0 (3)	0 (3)	0 (3)	0 (1)	0 (2)	NT
	IPD	74	25 (16)	47 (62)	56 (9)	28 (69)	27 (66)	23 (63)	63 (69)	80 (7)	75 (21)	25 (8)
	ICU	395	6 (50)	14 (158)	43 (7)	7 (190)	12 (167)	12 (158)	10 (178)	25 (10)	NT	14 (22)

Gram Negative Bacilli	Location	Isolates (n)	Tobramycin%(n)	Gentamicin%(n)	Amikacin%(n)	Ceftriaxone%(n)	Piperacillin/tazobactam%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Aztreonam%(n)	Chloramphenicol%(n)	Ceftazidime%(n)
<i>Klebsiella pneumoniae</i>	OPD	3	NT	33 (3)	NT	0 (3)	0 (3)	0 (3)	0 (3)	0 (1)	0 (2)	NT
	IPD	71	25 (16)	47 (62)	56 (9)	24 (66)	22 (64)	13 (60)	27 (68)	60 (5)	50 (20)	25 (8)
	ICU	188	6 (48)	26 (150)	43 (7)	10 (180)	11 (156)	12 (147)	20 (168)	25 (8)	29 (26)	14 (22)
<i>Klebsiella oxytoca</i>	IPD	3	NT	NT	NT	33 (3)	33 (3)	33 (3)	100 (1)	100 (2)	100 (1)	NT
	ICU	8	0 (1)	27 (7)	NT	12 (8)	12 (8)	0 (8)	12 (8)	0 (1)	NT	NT
<i>Enterobacter spp.</i>	OPD	5	NT	75 (4)	NT	40 (5)	50 (4)	50 (4)	75 (4)	NT	100 (4)	100 (1)
	IPD	78	43 (14)	51 (59)	13 (8)	20 (70)	27 (68)	13 (63)	37 (71)	60 (10)	71 (211)	17 (12)
	ICU	101	12 (17)	40 (71)	0 (3)	11 (92)	15 (88)	13 (87)	13 (92)	17 (6)	45 (22)	13 (16)
<i>Pseudomonas aeruginosa</i>	OPD	1	100 (1)	NBP	NBP	IR	100 (1)	NT	100 (1)	0 (1)	IR	0 (1)
	IPD	30	56 (18)	NBP	NBP	IR	59 (22)	53 (15)	42 (26)	36 (11)	IR	36 (11)
	ICU	44	69 (35)	NBP	NBP	IR	81 (37)	75 (12)	56 (41)	52 (23)	IR	73 (30)
<i>Salmonella Typhi</i>	OPD	1	IR	IR	IR	100 (1)	NBP	NT	NBP	NBP	0 (1)	NT
	IPD	6	IR	IR	IR	100 (6)	NBP	0 (1)	NBP	NBP	83 (6)	NT


Gram Negative Bacilli	Location	Isolates (n)	Tobramycin%(n)	Gentamicin%(n)	Amikacin%(n)	Ceftriaxone%(n)	Piperacillin/tazobactam%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Aztreonam%(n)	Chloramphenicol%(n)	Ceftazidime%(n)
<i>Salmonella Paratyphi A</i>	OPD	2	IR	IR	IR	100 (2)	NBP	0 (1)	NBP	NBP	100 (2)	NT
<i>Salmonella Paratyphi B</i>	OPD	1	IR	IR	IR	100 (1)	NBP	0 (1)	NBP	NBP	100 (1)	NT
<i>Citrobacter spp.</i>	OPD	7	NT	50 (2)	NT	0 (3)	0 (4)	50 (4)	50 (4)	NT	NT	100 (3)
	IPD	138	NT	100 (62)	41 (8)	40 (72)	78 (69)	40 (71)	75 (82)	NT	NT	32 (14)
	ICU	86	NT	36 (44)	0 (6)	27 (49)	23 (47)	25 (46)	33 (58)	NT	NT	33 (6)
<i>Citrobacter freundii</i>	OPD	2	NT	50 (2)	NT	0 (1)	0 (2)	50 (2)	50 (2)	NT	NT	100 (1)
	IPD	36	NT	75 (28)	0 (3)	34 (32)	56 (32)	38 (29)	51 (33)	100 (2)	80 (5)	25 (4)
	ICU	23	NT	25 (20)	0 (4)	9 (22)	5 (21)	10 (20)	27 (21)	0 (1)	NT	0 (2)
<i>Citrobacter koseri</i>	OPD	1	NT	NT	NT	0 (1)	0 (1)	0 (1)	0 (1)	NT	NT	0 (1)
	IPD	26	NT	35 (20)	33 (3)	15 (20)	26 (23)	13 (22)	50 (26)	0 (3)	100 (4)	0 (5)
	ICU	9	NT	29 (7)	NT	14 (7)	12 (8)	14 (7)	11 (9)	NT	NT	0 (1)
<i>Proteus mirabilis</i>	IPD	12	NT	60 (10)	0 (1)	55 (9)	54 (11)	58 (12)	IR	80 (5)	100 (2)	50 (2)
	ICU	5	NT	50 (4)	NT	0 (5)	0 (4)	25 (4)	IR	0 (1)	NT	NT
<i>Proteus vulgaris</i>	IPD	2	NT	100 (1)	NT	50 (2)	50 (2)	100 (2)	NT	100 (2)	NT	NT

ANTIBIOTIC SUSCEPTIBILITY OF BLOOD PATHOGENS JAN – DEC 2023


AST pattern of *Staphylococcus aureus* isolates from Blood specimen



AST pattern of *Acinetobacter baumannii* isolates from blood specimen



Distribution of bacterial isolates from Blood specimen



**ANTIBIOTIC SUSCEPTIBILITY
OF URINARY PATHOGENS
(JAN – DEC 2023)**

Antimicrobial susceptibility pattern for gram positive bacterial isolates from urine specimen

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	Isolates (n)	Cotrimoxazole%(n)	Cefoxitin%(n)	Tetracycline%(n)	Linezolid%(n)	Vancomycin%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	High level gentamicin%(n)	Gentamicin%(n)	Teicoplanin%(n)	Ciprofloxacin%(n)
<i>Staphylococcus aureus</i>	OPD	135	20 (100)	33 (98)	58 (105)	58 (105)	NBP	7 (31)	97 (86)	NBP	72 (78)	NBP	23 (43)
	IPD	36	0 (2)	35 (23)	59 (22)	59 (23)	NBP	7 (14)	80 (20)	NBP	81 (16)	NBP	0 (7)
	ICU	4	NT	0 (2)	0 (1)	0(1)	NBP	NT	0(1)	NBP	50(4)	NBP	100(1)
<i>MRSA</i>	OPD	64	29(7)	0 (64)	64(50)	100(41)	NBP	5(20)	45(40)	NBP	66(41)	NBP	18(17)
	IPD	14	NT	0(14)	50(8)	71(7)	NBP	0(5)	NT	NBP	71(7)	NBP	0(1)
	ICU	2	NT	0(2)	0(1)	100(1)	NBP	NT	NT	NBP	50(2)	NBP	NT
<i>MSSA</i>	OPD	71	NT	100(71)	54(55)	98(40)	NBP	9(11)	98(46)	NBP	78(37)	NBP	27(26)
	IPD	22	0(2)	100(22)	64(14)	100(9)	NBP	11(9)	85(13)	NBP	89(9)	NBP	0(6)
	ICU	2	NT	100(2)	NT	NT	NBP	NT	0(1)	NBP	50(2)	NBP	100(1)

Gram Positive Cocci	Location	Isolates (n)	Cotrimoxazole%(n)	Cefoxitin%(n)	Tetracycline%(n)	Linezolid%(n)	Vancomycin%(n)	Norfloracin%(n)	Nitrofurantoin%(n)	High level gentamicin%(n)	Gentamicin%(n)	Teicoplanin%(n)	Ciprofloxacin%(n)
CONS	OPD	37	NT	NT	NT	100(4)	NBP	6(18)	0(30)	NBP	65(17)	NBP	0(1)
	IPD	12	NT	17(6)	57(7)	100(2)	NBP	22(9)	82(11)	NBP	75(8)	NBP	NT
<i>Enterococcus faecalis</i>	OPD	132	IR	IR	16(109)	94(54)	33(3)	NT	94(84)	58(121)	IR	87(102)	10(42)
	IPD	103	IR	IR	12(86)	87(52)	100(2)	3(40)	73(64)	32(102)	IR	NT	8(40)
	ICU	13	IR	IR	0(8)	80(5)	NT	29(7)	100(8)	36(11)	IR	57(7)	0(5)
<i>Enterococcus spp.</i>	OPD	314	IR	IR	7(136)	97(80)	11(4)	16(23)	80(110)	72(156)	IR	91(137)	3(62)
	IPD	172	IR	IR	10(128)	87(83)	93(9)	12(69)	79(103)	29(132)	IR	57(50)	5(65)
	ICU	21	IR	IR	33(12)	93(10)	NT	26(9)	44(11)	25(19)	IR	94(14)	0(10)
<i>Enterococcus faecium</i>	OPD	37	IR	IR	5(21)	96(22)	0(1)	8(12)	86(21)	77(30)	IR	87(31)	0(16)
	IPD	50	IR	IR	10(29)	87(23)	80(5)	5(20)	63(27)	NT	IR	83(41)	6(17)
	ICU	5	IR	IR	100(1)	100(2)	NT	50(2)	33(3)	40(5)	IR	25(4)	0(2)

Antimicrobial susceptibility pattern for gram negative bacterial isolates from urine specimen




[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Tobramycin%(n)	Piperacillin- tazobactam%(n)	Ciprofloxacin%(n)	Meropenem%(n)	Amikacin%(n)	Ceftriaxone%(n)	Imipenem%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Cotrimoxazole%(n)	Ceftazidime%(n)
<i>Escherichia coli</i>	OPD	540	59(265)	41(68)	65(332)	100(1)	50(2)	44(9)	29(24)	74(26)	0(15)	30(30)	NT	68(6)
	IPD	420	50(174)	39(49)	46(257)	0(1)	NT	40(5)	30(30)	35(48)	0(17)	17(30)	NT	0(1)
	ICU	14	11(9)	33(3)	13(8)	NT	NT	NT	0(5)	25(4)	0(3)	0(4)	NT	0(3)
<i>Enterobacter spp.</i>	OPD	421	57(253)	42(36)	56(333)	0(8)	NT	47(30)	27(259)	78(359)	32(324)	73(409)	NT	28(18)
	IPD	245	55(117)	29(21)	39(183)	0(5)	NT	55(20)	15(142)	60(199)	20(211)	73(235)	50(2)	36(14)
	ICU	12	29(7)	0(1)	46(11)	NT	NT	0(1)	20(10)	50(12)	46(11)	46(11)	NT	0(1)
<i>Klebsiella pneumoniae</i>	OPD	129	67(87)	45(40)	62(138)	14(7)	71(7)	55(20)	54(80)	77(184)	48(180)	63(220)	100(1)	40(20)
	IPD	173	36(62)	36(33)	37(98)	0(4)	33(6)	32(22)	18(55)	52(142)	28(142)	43(161)	NT	100(1)
	ICU	12	0(8)	50(2)	13(8)	NT	NT	0(1)	8(65)	42(12)	18(11)	33(12)	NT	25(16)

Gram Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Tobramycin%(n)	Piperacillin-tazobactam%(n)	Ciprofloxacin%(n)	Meropenem%(n)	Amikacin%(n)	Ceftriaxone%(n)	Imipenem%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Cotrimoxazole%(n)	Ceftazidime%(n)
<i>Klebsiella oxytoca</i>	OPD	50	70(23)	20(5)	38(34)	NT	100(2)	63(8)	NT	NT	41(32)	57(49)	NT	NT
	IPD	47	44(25)	0(10)	24(29)	NT	100(1)	57(7)	NT	NT	24(37)	43(47)	NT	NT
	ICU	3	0(1)	100(1)	0(1)	NT	NT	NT	NT	NT	0(3)	67(3)	NT	NT
<i>Citrobacter koseri</i>	OPD	153	53(80)	0(3)	61(123)	NT	NT	75(4)	37(76)	79(140)	32(112)	79(146)	100(1)	63(8)
	IPD	88	45(41)	40(5)	53(70)	0(1)	NT	73(4)	24(50)	69(73)	34(77)	73(80)	NT	NT
	ICU	2	0(2)	NT	0(2)	NT	NT	0(1)	0(2)	0(2)	0(2)	0(2)	NT	NT
<i>Citrobacter freundii</i>	OPD	108	62(53)	62(53)	60(84)	NT	NT	100(6)	34(53)	72(9)	53(77)	73(101)	NT	58(12)
	IPD	65	28(36)	100(2)	41(51)	NT	NT	33(3)	8(38)	54(56)	17(53)	66(62)	NT	33(9)
	ICU	2	0(2)	0(1)	0(1)	NT	NT	NT	NT	50(2)	0(2)	0(1)	NT	NT
<i>Citrobacter spp.</i>	OPD	291	61(139)	54(58)	65(218)	NT	NT	25(10)	78(139)	72(160)	37(219)	72(266)	NT	59(33)
	IPD	178	24(83)	47(11)	44(129)	NT	NT	90(7)	15(96)	61(144)	23(154)	69(161)	NT	NT
	ICU	6	0(6)	0(5)	0(5)	NT	NT	NT	NT	50(6)	0(6)	17(5)	NT	NT
<i>Pseudomonas aeruginosa</i>	OPD	63	NBP	49(55)	84(38)	NT	NT	NT	IR	84(55)	57(42)	IR	IR	76(38)
	IPD	29	NBP	46(26)	60(20)	NT	NT	NT	IR	29(23)	67(15)	IR	IR	58(19)
	ICU	5	NBP	25(4)	20(5)	NT	NT	NT	IR	0(2)	0(1)	IR	IR	NT

Gram Negative Bacilli	Location	Isolates (n)	Gentamicin%(n)	Tobramycin%(n)	Piperacillin-tazobactam%(n)	Ciprofloxacin%(n)	Meropenem%(n)	Amikacin%(n)	Ceftriaxone%(n)	Imipenem%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)	Cotrimoxazole%(n)	Ceftazidime%(n)
<i>Acinetobacter baumannii</i>	OPD	53	69(26)	67(12)	72(29)	100(1)	50(2)	44(9)	29(24)	74(26)	NBP	NBP	NT	68(6)
	IPD	52	48(27)	0(4)	45(42)	0(1)	NT	40(5)	30(30)	35(48)	NBP	NBP	NT	0(1)
	ICU	7	40(5)	NT	20(5)	NT	NT	NT	0(5)	26(4)	NBP	NBP	NT	0(3)
<i>Proteus mirabilis</i>	OPD	31	50(8)	0(1)	80(2)	0(1)	100(1)	20(5)	55(11)	IR	24(25)	IR	0(1)	50(4)
	IPD	11	0(3)	0(1)	78(9)	NT	100(1)	100(1)	40(5)	IR	33(9)	IR	NT	100(1)
<i>Proteus vulgaris</i>	OPD	10	80(5)	0(5)	25(4)	NT	NT	NT	50(2)	40(5)	33(9)	IR	NT	50(2)
	IPD	4	100(2)	0(1)	NT	NT	NT	NT	NT	0(1)	0(4)	IR	NT	NT
<i>Proteus spp.</i>	OPD	45	65(13)	0(1)	68(10)	0(1)	100(3)	31(9)	43(17)	40(5)	27(38)	IR	0(1)	50(6)
	IPD	15	100(5)	0(1)	73(19)	NT	100(1)	100(1)	40(5)	0(1)	16(13)	IR	NT	100(1)

ANTIBIOTIC SUSCEPTIBILITY OF URINARY PATHOGENS JAN – DEC 2023



**ANTIBIOTIC
SUSCEPTIBILITY OF
CSF PATHOGENS
(JAN – DEC 2023)**

Antimicrobial susceptibility pattern for gram positive bacterial isolates from CSF specimen

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]


Gram Positive Cocci	Location	Isolates (n)	Cotrimoxazole%(n)	Vancomycin%(n)	Linezolid%(n)	High level Gentamicin%(n)	Gentamicin%(n)
<i>Staphylococcus aureus</i>	IPD	42	30.8(13)	NT	100(21)	NBP	66.7(12)
	ICU	14	50(2)	NT	100(9)	NBP	57.1(7)
<i>CONS</i>	IPD	18	22.6(7)	NT	100(7)	NBP	70(10)
	ICU	2	NT	NT	100(2)	NBP	100(1)
<i>Enterococcus spp.</i>	IPD	9	IR	0(1)	100(3)	83(6)	IR
	ICU	2	IR	0(1)	NT	100(2)	IR
<i>Enterococcus faecalis</i>	IPD	5	IR	0(1)	100(2)	66.7(3)	IR
	ICU	2	IR	0(1)	100(1)	0(2)	IR
<i>Enterococcus faecium</i>	ICU	2	IR	0(1)	100(1)	0(2)	IR

Antimicrobial susceptibility pattern for gram negative bacterial isolates from CSF specimen
[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]


Gram Negative Bacilli	Location	Isolates (n)	Ceftriaxone%(n)	Gentamicin%(n)	Cotrimoxazole%(n)	Piperacillin /Tazobactam%(n)	Amikacin%(n)	Tobramycin%(n)	Ceftazidime%(n)	Aztreonam%(n)
<i>Acinetobacter baumannii</i>	IPD	29	13.6(22)	64.3(14)	22.2(9)	29.2(24)	50(2)	66.7(3)	42.9(7)	IR
	ICU	5	0(4)	0(2)	NT	20(5)	NT	NT	0(1)	IR
<i>Pseudomonas aeruginosa</i>	IPD	12	IR	NBP	IR	57.1(7)	NBP	57.1(7)	42.9(7)	66.7(3)
	ICU	1	IR	NBP	IR	100(1)	NBP	NT	100(1)	100(1)
<i>Escherichia coli</i>	IPD	11	10(10)	50(4)	0(3)	37.5(8)	100(1)	50(2)	50(2)	0(1)
	ICU	3	33.3(3)	100(2)	NT	100(3)	100(1)	NT	NT	NT
<i>Klebsiella pneumoniae</i>	IPD	7	NT	60(5)	0(1)	33.3(6)	0(2)	NT	0(1)	NT
	ICU	3	0(3)	0(2)	0(2)	33.3(3)	NT	NT	NT	NT
<i>Enterobacter spp.</i>	IPD	9	37.5(8)	33.3(6)	0(2)	42.9(7)	0(1)	66.7(3)	0(2)	50(2)
	ICU	5	33.3(3)	50(2)	NT	50(4)	100(1)	66.7(3)	0(2)	50(2)
<i>Citrobacter koseri</i>	IPD	3	0(2)	100(1)	NT	0(1)	100(1)	NT	0(1)	50(2)

ANTIBIOTIC SUSCEPTIBILITY OF CSF PATHOGENS JAN – DEC 2023


AST pattern of *Staphylococcus aureus* isolates from CSF specimen



AST pattern of *Acinetobacter baumannii* isolates from CSF specimen



Distribution of bacterial isolates from CSF specimen




**ANTIBIOTIC
SUSCEPTIBILITY OF
ENTERIC PATHOGENS
(JAN – DEC 2023)**

Antimicrobial susceptibility pattern for gram negative bacterial isolates from stool specimen

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Organism	Location	Isolates (n)	Amikacin%(n)	Piperacillin/Tazobactam%(n)	Ceftriaxone%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Cotrimoxazole%(n)	Chloramphenicol%(n)	Ceftazidime%(n)	Penicillin%(n)	Spectinomycin%(n)	Cefpodoxime%(n)	Cefotaxime%(n)	Azithromycin%(n)
<i>Diarrheagenic Escherichia coli</i>	OPD	31	42(29)	0(2)	25(28)	13(31)	43(23)	NT	NT	0(3)	NT	NBP	NBP	NT	IR
	IPD	18	42(12)	25(4)	17(12)	12(17)	71(17)	27(15)	NT	NT	NT	NBP	NBP	0(2)	IR
	ICU	3	67(3)	NT	50(2)	50(2)	NT	0(3)	NT	NT	NT	NBP	NBP	0(1)	IR
<i>Klebsiella oxytoca</i>	OPD	3	100(2)	NT	0(3)	0(3)	0(2)	NT	100(1)	NT	NT	NBP	NBP	NT	IR
	IPD	2	NT	NT	0(2)	0(2)	0(2)	NT	NT	NT	NT	NBP	NBP	NT	IR
<i>Klebsiella pneumoniae</i>	OPD	2	0(1)	NT	50(2)	50(2)	50(2)	0(1)	NT	NT	NT	NBP	NBP	NT	IR
	IPD	2	100(1)	NT	50(2)	NT	100(2)	100(2)	NT	NT	NT	NBP	NBP	NT	IR
<i>Salmonella Typhi</i>	OPD	2	IR	NBP	NT	50(2)	NBP	50(2)	NT	NT	NBP	NBP	NBP	NT	NT
<i>Neisseria gonorrhoeae</i>	OPD	1	NBP	NBP	100(1)	100(1)	NBP	NBP	NBP	NBP	0(1)	100(1)	100(1)	NT	0(1)



**DEPARTMENT WISE
ANTIMICROBIAL
SUSCEPTIBILITY PATTERNS**

**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM
MEDICINE DEPARTMENT
(JAN – DEC 2023)**

Antimicrobial susceptibility for gram positive pathogens from Medicine department

[% of susceptible (total number of isolates tested for a given antibiotic) = % (n)]

Gram Positive Cocci	Location	Number of isolates	Cefoxitin %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Cotrimoxazole %(n)	Clindamycin %(n)	Erythromycin %(n)	Linezolid %(n)	Chloramphenicol %(n)	Tetracycline %(n)	Nitrofurantoin %(n)	Norfloxacin %(n)
MRSA	OPD	45	0 (45)	75 (16)	0 (6)	50 (6)	38 (29)	7 (29)	97 (29)	100 (2)	50 (32)	100 (12)	0 (7)
	IPD	235	0 (235)	60 (97)	12 (140)	28 (61)	37 (210)	6 (216)	97 (104)	77 (85)	50 (58)	50 (2)	NT
	ICU	39	0 (39)	25 (16)	16 (19)	18 (11)	25 (36)	8 (36)	93 (15)	88 (17)	36 (11)	NT	NT
MSSA	OPD	20	100 (20)	90 (11)	14 (7)	100 (3)	90 (10)	44 (9)	100 (11)	100 (3)	54 (13)	100 (6)	0 (1)
	IPD	123	100 (123)	80 (51)	53 (77)	48 (33)	59 (105)	32 (111)	100 (53)	87 (39)	63 (30)	100 (1)	NT
	ICU	12	100 (12)	50 (4)	25 (8)	50 (2)	55 (9)	20 (10)	100 (5)	50 (4)	50 (4)	NT	NT
Staphylococcus aureus	OPD	97	21 (97)	80 (30)	15 (26)	60 (20)	55 (56)	19 (64)	96 (52)	89 (18)	58 (63)	100 (23)	0 (10)
	IPD	527	31 (501)	68 (179)	26 (332)	35 (108)	46 (391)	15 (482)	98 (276)	83 (200)	63 (168)	75 (4)	0 (2)
	ICU	71	17 (71)	39 (26)	23 (39)	20 (15)	33 (54)	11 (63)	97 (32)	75 (28)	50 (24)	0 (1)	NT
CONS	OPD	18	0 (6)	75 (4)	0 (2)	NT	67 (3)	20 (5)	100 (4)	67 (3)	50 (12)	92 (12)	0 (9)
	IPD	84	22 (37)	75 (32)	32 (37)	45 (11)	55 (58)	18 (65)	95 (43)	62 (16)	57 (42)	100 (2)	50 (2)
	ICU	13	20 (5)	67 (6)	12 (8)	25 (4)	55 (11)	16 (13)	100 (5)	75 (4)	25 (4)	NT	NT

Gram Positive Cocci	Location	Number of isolates	High level gentamicin%(n)	Ciprofloxacin %(n)	Erythromycin %(n)	Linezolid %(n)	Vancomycin %(n)	Chloramphenicol %(n)	Tetracycline %(n)	Teicoplanin %(n)	Nitrofurantoin %(n)
<i>Enterococcus faecalis</i>	OPD	43	46 (35)	7 (15)	0 (3)	95 (21)	67 (3)	100 (1)	19 (31)	87 (32)	96 (25)
	IPD	64	41 (54)	0 (20)	0 (20)	96 (27)	100 (6)	92 (13)	10 (31)	68 (25)	84 (25)
	ICU	11	44 (9)	0 (3)	0 (1)	80 (5)	NT	NT	0 (6)	80 (5)	100 (7)
<i>Enterococcus faecium</i>	OPD	14	0 (11)	0 (7)	0 (2)	0 (10)	NT	0 (1)	0 (7)	0 (12)	0 (6)
	IPD	27	56 (25)	0 (5)	22 (9)	100 (10)	33 (6)	71 (7)	13 (8)	88 (16)	70 (10)
	ICU	5	80 (5)	0 (1)	33 (3)	100 (2)	50 (2)	50 (2)	100 (1)	60 (5)	50 (2)
<i>Enterococcus spp.</i>	OPD	60	49 (49)	2 (25)	0 (5)	65 (24)	67 (3)	50 (2)	6 (41)	62 (47)	48 (31)
	IPD	110	66 (87)	0 (35)	7 (31)	99 (42)	78 (14)	77 (23)	8 (43)	85 (46)	84 (39)
	ICU	38	58 (32)	0 (11)	19 (8)	90 (18)	50 (4)	50 (4)	37 (17)	72 (23)	80 (18)
<i>Streptococcus spp.</i>	OPD	1	NBP	NBP	0 (1)	100 (1)	NT	0 (1)	NT	NBP	NBP
	IPD	5	NBP	NBP	75 (4)	100 (2)	100 (1)	100 (4)	NT	NBP	NBP
	ICU	1	NBP	NBP	NT	NT	NT	0 (1)	100 (1)	NBP	NBP


Antimicrobial susceptibility for gram negative pathogens from Medicine department

[% of susceptible (total number of isolates tested for a given antibiotic)]

Gram Negative Bacilli	Location	Number of isolates	Ceftriaxone % (n)	Piperacillin-tazobactam % (n)	Gentamicin % (n)	Ciprofloxacin % (n)	Cotrimoxazole % (n)	Nitrofurantoin % (n)	Imipenem % (n)	Meropenem % (n)	Tobramycin % (n)	Amikacin % (n)	Tetracycline % (n)	Aztreonam % (n)	Ceftazidime % (n)	Norfloxacin % (n)	Chloramphenicol % (n)
<i>Escherichia coli</i>	OPD	142	34 (78)	78 (101)	72 (82)	18 (11)	NT	86 (127)	82 (125)	100 (1)	53 (19)	77 (26)	NT	0 (1)	40 (10)	27 (113)	89 (9)
	IPD	309	27 (191)	55 (212)	69 (152)	20 (94)	0 (4)	82 (164)	61 (252)	100 (1)	61 (128)	45 (40)	0 (10)	50 (10)	21 (51)	15 (178)	88 (45)
	ICU	29	9 (23)	23 (22)	44 (18)	8 (13)	NT	71 (7)	32 (22)	0 (1)	0 (3)	0 (5)	NT	0 (2)	0 (7)	0 (9)	50 (2)
<i>Enterobacter spp.</i>	OPD	162	37 (120)	69 (132)	72 (107)	56 (25)	0 (1)	73 (121)	73 (145)	NT	80 (5)	NT	NT	100 (3)	46 (11)	28 (88)	100 (9)
	IPD	193	15 (143)	46 (141)	50 (112)	14 (59)	33 (67)	77 (88)	53 (155)	100 (3)	42 (19)	35 (17)	NT	42 (14)	30 (26)	16 (24)	NT
	ICU	60	2 (51)	21 (51)	31 (38)	8 (40)	NT	33 (9)	15 (52)	NT	16 (6)	40 (5)	NT	20 (5)	0 (11)	33 (9)	50 (8)
<i>Klebsiella pneumoniae</i>	OPD	137	57 (94)	63 (107)	70 (27)	51 (51)	NT	48 (54)	70 (128)	100 (1)	55 (18)	52 (42)	NT	80 (5)	41 (17)	47 (40)	78 (9)
	IPD	197	21 (130)	40 (131)	49 (95)	16 (83)	0 (3)	45 (62)	43 (165)	33 (3)	36 (25)	41 (34)	50 (2)	23 (13)	8 (25)	15 (59)	69 (23)
	ICU	59	4 (54)	18 (51)	6 (32)	5 (36)	NT	27 (11)	20 (54)	NT	27 (11)	0 (11)	NT	40 (5)	20 (5)	10 (10)	40 (5)
<i>Klebsiella oxytoca</i>	OPD	15	14 (7)	33 (12)	50 (8)	NT	NT	50 (14)	61 (13)	100 (1)	0 (1)	33 (3)	NT	NT	NT	28 (7)	NT
	IPD	26	11 (17)	47 (21)	43 (16)	12 (8)	NT	35 (17)	54 (22)	NT	50 (2)	50 (4)	NT	100 (1)	0 (2)	23 (13)	50 (2)
	ICU	4	25 (4)	33 (3)	0 (2)	0 (3)	NT	NT	33 (3)	NT	0 (1)	0 (1)	NT	50 (2)	100 (1)	NT	NT
<i>Klebsiella spp.</i>	OPD	152	36 (101)	48 (119)	60 (35)	51 (51)	NT	49 (68)	66 (141)	100 (2)	28 (19)	43 (45)	NT	80 (5)	41 (17)	38 (47)	78 (9)
	IPD	223	16 (147)	44 (152)	36 (111)	14 (91)	0 (3)	40 (79)	49 (187)	33 (3)	43 (27)	46 (38)	50 (2)	62 (14)	4 (27)	19 (72)	60 (25)
	ICU	63	15 (58)	26 (54)	3 (34)	3 (39)	NT	27 (11)	27 (57)	NT	14 (12)	0 (12)	NT	45 (7)	60 (6)	10 (10)	40 (5)
<i>Acinetobacter baumannii</i>	OPD	31	13 (22)	26 (23)	NBP	0 (15)	0 (1)	NBP	27 (29)	NT	67 (3)	25 (4)	NT	IR	50 (4)	NBP	IR
	IPD	145	8 (109)	31 (105)	NBP	26 (84)	25 (8)	NBP	23 (117)	0 (2)	47 (17)	14 (14)	0 (1)	IR	0 (21)	NBP	IR
	ICU	181	NT	8 (141)	NBP	14 (124)	NT	NBP	3 (158)	NT	11 (17)	0 (27)	0 (1)	IR	4 (26)	NBP	IR

Gram Negative Bacilli	Location	Number of isolates	Ceftriaxone %(n)	Cefotaxime %(n)	Piperacillin-tazobactam %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Nitrofurantoin %(n)	Imipenem %(n)	Meropenem %(n)	Tobramycin %(n)	Amikacin %(n)	Aztreonam %(n)	Ceftazidime %(n)	Norfloracin %(n)	Chloramphenicol %(n)
<i>Pseudomonas aeruginosa</i>	OPD	42	IR	IR	94 (33)	NBP	70 (23)	IR	86 (37)	NT	83 (36)	100 (1)	75 (12)	81 (31)	43 (7)	IR
	IPD	87	IR	IR	63 (57)	NBP	56 (34)	IR	62 (64)	NT	77 (76)	100 (2)	51 (37)	65 (63)	75 (8)	IR
	ICU	35	IR	IR	46 (30)	NBP	44 (16)	IR	26 (31)	NT	29 (28)	NT	33 (9)	39 (18)	0 (1)	IR
<i>Citrobacter koseri</i>	OPD	44	NT	35 (26)	63 (36)	67 (27)	13 (8)	83 (36)	69 (42)	NT	0 (2)	100 (3)	33 (3)	0 (1)	22 (27)	NT
	IPD	70	17 (40)	0 (3)	51 (54)	56 (37)	13 (22)	71 (28)	62 (53)	66 (3)	23 (6)	50 (4)	20 (10)	29 (17)	25 (31)	100 (6)
	ICU	11	10 (10)	NT	0 (9)	30 (10)	10 (10)	0 (1)	9 (11)	NT	NT	0 (2)	NT	0 (2)	0 (1)	50 (2)
<i>Citrobacter freundii</i>	OPD	40	20 (25)	NT	60 (30)	86 (2)	NT	NT	76 (33)	NT	NT	100 (2)	100 (3)	100 (2)	NT	NT
	IPD	68	15 (51)	NT	57 (57)	54 (42)	23 (13)	76 (26)	55 (61)	NT	60 (5)	20 (5)	30 (10)	42 (7)	17 (23)	77 (9)
	ICU	13	15 (13)	NT	11 (9)	25 (12)	0 (12)	NT	25 (12)	NT	0 (1)	NT	20 (5)	NT	NT	NT
<i>Citrobacter spp.</i>	OPD	88	10 (27)	35 (26)	43 (68)	84 (30)	8 (9)	67 (38)	59 (78)	NT	0 (2)	100 (5)	67 (6)	50 (5)	28 (30)	NT
	IPD	169	18 (108)	0 (3)	57 (128)	62 (92)	20 (48)	66 (64)	56 (136)	33 (4)	16 (14)	32 (13)	33 (22)	31 (33)	18 (69)	72 (20)
	ICU	38	8 (34)	NT	13 (32)	31 (30)	6 (33)	25 (3)	16 (36)	NT	0 (3)	17 (5)	20 (5)	0 (4)	0 (3)	25 (3)
<i>Proteus spp.</i>	OPD	13	13 (5)	NT	69 (10)	75 (5)	50 (4)	IR	IR	100 (1)	0 (1)	0 (1)	NT	NT	54 (7)	50 (2)
	IPD	23	37 (17)	NT	74 (20)	50 (14)	31 (17)	IR	IR	100 (1)	100 (1)	50 (2)	42 (7)	33 (5)	50 (2)	100 (2)
	ICU	5	50 (5)	NT	0 (3)	67 (3)	33 (3)	IR	IR	NT	67(3)	NT	100 (1)	NT	NT	100 (1)
<i>Salmonella spp.</i>	OPD	4	100 (4)	NT	NBP	NBP	0 (2)	NBP	NT	NT	NBP	NBP	NBP	NBP	NBP	NBP
	IPD	6	100 (5)	NT	NBP	NBP	0 (2)	NBP	100 (1)	NT	NBP	NBP	NBP	NBP	NBP	NBP

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM MEDICINE DEPARTMENT JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS
ISOLATED FROM SURGERY DEPARTMENT
(JAN – DEC 2023)**

Antimicrobial susceptibility for gram positive pathogens from Surgery department

[% of susceptible (total number of isolates tested for a given antibiotic)= %(n)]

Gram Positive Cocci	Location	Number of isolates	Cefoxitin %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Trimethoprim/Sulfamethoxazole %(n)	Clindamycin %(n)	Erythromycin %(n)	Nitrofurantoin %(n)	Chloramphenicol %(n)	Tetracycline %(n)
MRSA	OPD	181	0 (155)	62 (37)	14 (22)	64 (14)	62 (164)	20 (167)	100 (10)	85 (39)	49 (133)
	IPD	144	0 (129)	42 (12)	6 (18)	68 (19)	47 (140)	15 (139)	50 (2)	78 (23)	38 (112)
	ICU	1	0 (1)	100 (1)	NT	NT	100 (1)	100 (1)	NT	NT	NT
MSSA	OPD	64	100 (64)	100 (12)	10 (10)	100 (1)	75 (56)	36 (56)	100 (4)	100 (16)	74 (46)
	IPD	68	100 (68)	64 (11)	10 (10)	0 (2)	76 (66)	33 (67)	100 (1)	91 (23)	61 (47)
Staphylococcus aureus	OPD	386	26 (217)	68 (59)	9 (86)	70 (61)	66 (309)	24 (349)	100 (22)	91 (99)	60 (276)
	IPD	360	25 (191)	49 (31)	12 (109)	60 (51)	58 (266)	21 (348)	75 (4)	93 (100)	53 (235)
	ICU	1	0 (1)	100 (1)	NT	NT	NT	NT	NT	NT	NT
CONS	OPD	74	39 (34)	71 (7)	10 (10)	61 (13)	51 (63)	26 (66)	100 (6)	64 (25)	45 (45)
	IPD	57	7 (28)	77 (13)	36 (11)	37 (8)	38 (47)	18 (54)	0 (1)	86 (14)	69 (36)
	ICU	1	0 (1)	100 (1)	100 (1)	100 (1)	100 (1)	0 (1)	NT	NT	NT

Gram Positive Cocci	Location	Number of isolates	Ciprofloxacin %(n)	Erythromycin %(n)	Nitrofurantoin %(n)	Teicoplanin %(n)	Chloramphenicol %(n)	Tetracycline %(n)	Vancomycin %(n)	High level Gentamicin %(n)
<i>Enterococcus faecium</i>	OPD	12	0 (5)	0 (2)	100 (7)	80 (10)	67 (3)	0 (7)	0 (1)	80 (10)
	IPD	8	0 (5)	17 (6)	100 (2)	100 (4)	67(6)	25 (4)	NT	33 (6)
<i>Enterococcus faecalis</i>	OPD	55	6 (17)	14 (7)	100 (29)	85 (39)	100 (2)	9 (45)	40 (5)	60 (53)
	IPD	30	9 (11)	6 (16)	100 (2)	80 (5)	86 (14)	0 (9)	70 (10)	50 (26)
<i>Enterococcus spp.</i>	OPD	91	0 (2)	NT	67 (33)	100 (1)	100 (2)	0 (4)	NT	100 (3)
	IPD	45	50 (2)	NT	100 (2)	NT	NT	100 (1)	NT	75 (4)


Antimicrobial susceptibility for gram negative pathogens from Surgery department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacilli	Location	Number of isolates	Ceftriaxone %(n)	Amoxicillin/clavulanic acid %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Piperacillin/tazobactam %(n)	Amikacin %(n)	Tobramycin %(n)	Imipenem %(n)	Meropenem %(n)	Ceftazidime %(n)	Aztreonam %(n)	Norfloxacin %(n)	Chloramphenicol %(n)	Nitrofurantoin %(n)
<i>Enterobacter species</i>	OPD	248	22 (169)	IR	44 (146)	20 (71)	45 (193)	35 (20)	30 (20)	61 (210)	50 (2)	21 (19)	22 (9)	32 (121)	75 (24)	65 (142)
	IPD	222	12 (171)	IR	42 (113)	10 (139)	22 (159)	27 (55)	11 (9)	35 (179)	60 (5)	22 (27)	26 (27)	25 (28)	82 (22)	67 (36)
	ICU	2	0(2)	IR	0 (1)	0 (1)	0 (1)	NT	0 (1)	0 (1)	NT	NT	0 (1)	NT	NT	NT
<i>Escherichia coli</i>	OPD	282	19 (155)	35 (17)	53 (143)	9 (58)	50 (184)	26 (34)	47 (32)	72 (234)	100 (2)	28 (32)	60 (5)	19 (181)	96 (27)	81 (196)
	IPD	267	8 (212)	46 (13)	37 (115)	3 (151)	21 (193)	24 (46)	30 (20)	43 (223)	50 (8)	23 (31)	17 (6)	25 (40)	85 (55)	85 (41)
	ICU	1	0 (1)	NT	NT	NT	NT	NT	NT	NT	NT	NT	0 (1)	NT	NT	NT
<i>Klebsiella pneumoniae</i>	OPD	157	44 (91)	33 (3)	60 (67)	15 (46)	47 (100)	45 (31)	38 (21)	55 (131)	50 (4)	13 (15)	50 (6)	50 (66)	75 (8)	65 (76)
	IPD	178	23 (141)	67 (9)	35 (75)	14 (93)	100 (141)	27 (62)	32 (28)	41 (159)	0 (3)	32 (28)	100 (6)	38 (16)	56 (16)	48 (28)
	ICU	3	0 (2)	NT	100 (1)	0 (2)	NT	0 (2)	0 (1)	50 (2)	NT	NT	NT	NT	NT	NT
<i>Klebsiella oxytoca</i>	OPD	28	50 (14)	75 (4)	83 (12)	33 (3)	52 (21)	50 (6)	33 (3)	73 (22)	100 (1)	33 (3)	100 (2)	36 (14)	NT	6 (7(3))
	IPD	24	16 (19)	50 (2)	46 (11)	6 (16)	19 (16)	33 (3)	50 (2)	29 (21)	NT	0 (1)	50 (2)	25 (14)	33 (3)	25 (4)
<i>Klebsiella spp.</i>	OPD	276	40 (105)	50 (7)	70 (79)	30 (49)	50 (121)	50 (37)	35 (24)	50 (153)	75 (5)	20 (18)	58 (8)	40 (80)	75 (8)	50 (79)
	IPD	202	30 (160)	50 (11)	30 (86)	20 (109)	50 (157)	30 (65)	40 (30)	30 (180)	0 (3)	30 (29)	50 (8)	30 (30)	40 (19)	30 (32)
	ICU	3	0 (2)	NT	100 (1)	0 (2)	NT	0 (2)	0 (1)	50 (2)	NT	NT	NT	NT	NT	NT
<i>Pseudomonas aeruginosa</i>	OPD	148	IR	IR	NBP	44 (55)	75 (106)	50 (2)	60 (133)	72 (114)	100 (1)	65 (112)	70 (50)	54 (26)	IR	IR
	IPD	107	IR	IR	NBP	29 (56)	64 (80)	0 (1)	56 (90)	61 (84)	0 (1)	59 (78)	62 (60)	0 (2)	IR	IR

Gram Negative Bacilli	Location	Number of isolates	Ceftriaxone %(n)	Cefotaxime %(n)	Amoxicillin/clavulanic acid %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Piperacillin/tazobactam %(n)	Amikacin %(n)	Tobramycin %(n)	Imipenem %(n)	Meropenem %(n)	Ceftazidime %(n)	Aztreonam %(n)	Norfloracin %(n)	Chloramphenicol %(n)	Nitrofurantoin %(n)
<i>Proteus mirabilis</i>	OPD	53	65 (34)	NT	NT	62 (26)	27 (30)	NT	83 (12)	20 (5)	IR	NT	29 (7)	100 (3)	20 (10)	25 (4)	IR
	IPD	40	45 (31)	50 (2)	NT	47 (19)	10 (29)	64 (28)	40 (5)	20 (5)	IR	100 (1)	40 (10)	NT	0 (2)	33 (6)	IR
<i>Proteus vulgaris</i>	OPD	15	62 (8)	NT	100 (1)	57 (7)	33 (6)	70 (10)	50 (2)	0 (4)	50 (6)	NT	50 (4)	NT	33 (6)	0 (1)	IR
	IPD	11	50 (10)	NT	33 (3)	25 (4)	0 (2)	100 (3)	NT	NT	0 (3)	NT	40 (5)	100 (4)	0 (1)	100 (1)	IR
<i>Proteus spp.</i>	OPD	68	65 (42)	NT	100 (1)	57 (33)	30 (36)	70 (10)	80 (14)	20 (9)	50 (6)	NT	40 (11)	100 (3)	30 (16)	25 (5)	IR
	IPD	51	45 (41)	50 (2)	33 (3)	40 (23)	10 (31)	81 (31)	40 (5)	20 (5)	0 (3)	100 (1)	40 (15)	100 (4)	0 (3)	81 (7)	IR
<i>Citrobacter freundii</i>	OPD	86	44 (62)	0 (1)	IR	68 (53)	24 (37)	41 (66)	71 (7)	100 (1)	64 (73)	NT	50 (11)	36 (14)	46 (26)	80 (5)	61 (31)
	IPD	73	24 (63)	0 (2)	IR	67 (33)	19 (42)	31 (49)	33 (6)	33 (3)	51 (55)	0 (1)	36 (11)	47 (19)	17 (6)	73 (11)	50 (8)
<i>Citrobacter koseri</i>	OPD	75	33 (46)	NT	0 (1)	71 (41)	19 (26)	44 (59)	33 (6)	33 (3)	74 (65)	100 (1)	NT	0 (1)	41 (29)	50 (6)	85 (39)
	IPD	66	16 (56)	0 (1)	NT	40 (30)	13 (40)	28 (54)	30 (10)	29 (7)	45 (62)	100 (2)	10 (10)	25 (4)	38 (8)	83 (6)	78 (9)
	ICU	2	0 (2)	NT	100 (1)	0 (1)	NT	0 (1)	NT	NT	0 (1)	NT	NT	0 (1)	0 (1)	NT	0 (1)
<i>Citrobacter spp.</i>	OPD	191	19 (124)	0 (1)	NT	60 (99)	0 (63)	31 (141)	100 (15)	100 (5)	39 (156)	0 (2)	40 (21)	36 (15)	29 (72)	50 (15)	70 (80)
	IPD	200	14 (168)	0 (3)	NT	33 (78)	8 (130)	16 (154)	43 (30)	27 (21)	37 (156)	0 (4)	0 (27)	25 (27)	50 (16)	89 (26)	100 (19)
	ICU	2	0 (2)	NT	100 (1)	0 (1)	NT	0 (1)	NT	NT	0 (1)	NT	NT	0 (1)	0 (1)	NT	0 (1)
<i>Acinetobacter baumannii</i>	OPD	62	7 (92)	0 (1)	IR	30 (40)	16 (32)	41 (44)	60 (5)	36 (11)	39 (55)	33 (3)	40 (5)	IR	NBP	IR	NBP
	IPD	146	10 (98)	0 (3)	IR	18 (73)	11 (91)	19 (119)	3 (33)	6 (16)	17 (132)	0 (4)	11 (18)	IR	NBP	IR	NBP
	ICU	5	0 (5)	NT	IR	0 (1)	NT	0 (2)	0 (1)	NT	0 (2)	NT	NT	IR	NBP	IR	NBP

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM SURGERY DEPARTMENT JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM
PEDIATRIC DEPARTMENT
(JAN – DEC 2023)**

Antimicrobial susceptibility for gram positive pathogens from Pediatric department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram-Positive Cocci	Location	Number of isolates	Cefoxitin %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Clindamycin %(n)	Erythromycin%(n)	Linezolid %(n)
MRSA	OPD	33	0 (24)	58 (12)	70 (10)	42 (19)	10 (20)	100 (20)
	IPD	103	0 (89)	71 (45)	38 (63)	39 (97)	10 (96)	100 (40)
	ICU	124	0 (102)	54 (51)	28 (34)	31 (116)	10 (118)	100 (56)
MSSA	OPD	17	100 (12)	80 (5)	45 (11)	69 (13)	41 (12)	92 (13)
	IPD	68	92 (66)	82 (29)	62 (61)	61 (67)	27 (68)	97 (35)
	ICU	33	69 (29)	86 (15)	56 (23)	25 (32)	37 (32)	100 (13)
<i>Staphylococcus aureus</i>	OPD	63	35 (37)	70 (20)	27 (29)	53 (39)	17 (41)	97 (40)
	IPD	378	38 (159)	74 (90)	52 (197)	50 (204)	16 (265)	98 (149)
	ICU	191	15 (134)	62 (72)	35 (118)	43 (158)	17 (179)	100 (81)
CONS	OPD	21	0 (7)	100 (3)	25 (12)	25 (16)	0 (17)	100 (2)
	IPD	210	24 (148)	71 (109)	33 (158)	52 (186)	11 (199)	98 (121)
	ICU	250	9 (164)	65 (138)	18 (167)	31 (226)	7 (244)	99 (108)

Gram-Positive Cocci	Location	Number of isolates	Gentamicin (120) %(n)	Ciprofloxacin %(n)	Erythromycin %(n)	Linezolid %(n)	Vancomycin %(n)	Teicoplanin %(n)	Nitrofurantoin %(n)
<i>Enterococcus faecalis</i>	OPD	11	55 (9)	0 (1)	0 (2)	100 (3)	NT	83 (6)	85 (7)
	IPD	30	62 (24)	0 (9)	8 (12)	86 (15)	80 (5)	78 (19)	100 (7)
	ICU	14	46 (13)	0 (4)	25 (8)	71 (7)	50 (4)	33 (6)	100 (1)
<i>Enterococcus faecium</i>	OPD	4	50 (2)	0 (1)	NT	100 (3)	NT	100 (2)	100 (3)
	IPD	13	40 (10)	0 (5)	0 (4)	86 (15)	50 (2)	60 (10)	83 (6)
	ICU	7	50 (6)	0 (3)	0 (3)	71 (7)	100 (1)	60 (5)	0 (1)
<i>Enterococcus spp.</i>	OPD	22	52 (11)	0 (2)	0 (2)	100 (6)	NT	91 (8)	92 (10)
	IPD	49	59 (38)	0 (23)	54 (18)	95 (22)	50 (5)	69 (32)	94 (17)
	ICU	26	60 (24)	0 (7)	25 (11)	90 (13)	83 (10)	63 (12)	NT


Antimicrobial susceptibility for gram negative pathogens from Pediatric department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacilli	Location	No of isolates	Ceftriaxone %(n)	Amoxicillin/clavulanate %(n)	Piperacillin/tazobactam%(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Imipenem %(n)	Meropenem %(n)	Tobramycin %(n)	Amikacin %(n)	Ceftazidime %(n)	Norfloxacinn %(n)	Nitrofurantoin %(n)	Aztreonam %(n)
<i>Klebsiella pneumonia</i>	OPD	38	40 (15)	0 (2)	37 (19)	83 (12)	45 (5)	66 (30)	100 (2)	66 (9)	75 (4)	60 (5)	48 (25)	58 (31)	NT
	IPD	48	29 (39)	0 (2)	26 (38)	33 (33)	14 (28)	39 (44)	NT	27 (11)	57 (7)	28 (7)	25 (12)	40 (15)	67 (3)
	ICU	180	10 (169)	11 (27)	11 (145)	27 (141)	11 (137)	21 (154)	NT	6 (45)	50 (6)	10 (20)	NT	NT	0 (5)
<i>Escherichia coli</i>	OPD	91	38 (13)	66 (3)	67 (40)	74 (35)	12 (41)	60 (70)	NT	43 (7)	66 (33)	38 (13)	34 (46)	88 (51)	NT
	IPD	116	18 (11)	50 (2)	61 (83)	83 (75)	17 (70)	63 (104)	NT	47 (15)	48 (23)	18 (11)	19 (37)	74 (34)	43 (7)
	ICU	21	NT	0 (1)	54 (11)	46 (13)	33 (9)	54 (13)	0 (1)	0 (3)	50 (8)	NT	25 (4)	25 (4)	0 (1)
<i>Enterobacter spp.</i>	OPD	49	29 (34)	IR	60 (43)	84 (31)	60 (5)	79 (44)	NT	33 (3)	66 (3)	50 (2)	32 (28)	80 (41)	0 (1)
	IPD	59	22 (46)	IR	23 (52)	57 (35)	9 (32)	40 (52)	NT	57 (7)	40 (5)	17 (6)	10 (19)	62 (21)	15 (6)
	ICU	86	14 (78)	IR	22 (73)	42 (59)	13 (66)	18 (76)	50 (2)	17 (77)	14 (7)	13 (15)	100 (2)	100 (2)	50 (4)
<i>Acinetobacter spp.</i>	OPD	14	50 (5)	IR	62 (5)	50 (5)	50 (2)	41 (5)	NT	100 (2)	NT	100 (3)	NBP	NBP	IR
	IPD	89	40 (38)	IR	51 (35)	70 (31)	38 (29)	65 (34)	NT	52 (9)	100 (2)	66 (11)	NBP	NBP	IR
	ICU	195	36 (80)	IR	59 (81)	58 (71)	62 (67)	55 (79)	0 (2)	25 (8)	0 (9)	5 (21)	NBP	NBP	IR

Gram Negative Bacilli	Location	No of isolates	Ceftriaxone %(n)	Piperacillin/tazobactam %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Imipenem %(n)	Meropenem %(n)	Tobramycin %(n)	Amikacin %(n)	Ceftazidime %(n)	Norfloxacin %(n)	Nitrofurantoin %(n)	Aztreonam %(n)
<i>Citrobacter freundii</i>	OPD	6	6 7(3)	60 (5)	33 (3)	NT	60 (5)	NT	NT	NT	NT	67 (3)	83 (6)	NT
	IPD	22	44 (18)	50 (22)	77 (17)	27 (11)	60 (20)	NT	67 (3)	NT	0 (2)	14 (7)	75 (8)	100 (1)
	ICU	20	11 (18)	6 (16)	23 (17)	12 (16)	28 (18)	NT	0 (3)	0 (4)	0 (2)	0 (1)	0 (1)	0 (1)
<i>Citrobacter koseri</i>	OPD	18	11 (9)	50 (16)	66 (9)	NT	65 (17)	NT	NT	NT	NT	8 (12)	89 (18)	NT
	IPD	23	28 (18)	27 (21)	13 (15)	25 (8)	39 (23)	NT	67 (3)	0 (2)	0 (3)	25 (12)	71 (14)	0 (2)
	ICU	6	0 (5)	20 (5)	0 (3)	0 (3)	0 (6)	NT	NT	NT	0(1)	NT	NT	NT
<i>Citrobacter spp.</i>	OPD	25	0 (1)	70 (22)	50 (12)	NT	65 (25)	NT	NT	NT	0 (1)	37 (160)	90 (25)	100 (4)
	IPD	54	67 (8)	36 (50)	75 (36)	26 (24)	37 (51)	NT	67 (6)	100 (4)	67 (8)	20 (20)	80 (23)	100 (1)
	ICU	46	0 (3)	50 (5)	50 (4)	25 (36)	23 (33)	NT	18 (36)	0 (6)	50 (3)	0 (2)	20 (42)	100 (3)
<i>Pseudomonas aeruginosa</i>	OPD	13	IR	75 (8)	NBP	50 (2)	82 (11)	NT	73 (11)	NT	50 (6)	60 (5)	IR	NT
	IPD	20	IR	57 (14)	NBP	55 (11)	67 (15)	NT	55 (11)	NT	44 (9)	NT	IR	60 (5)
	ICU	36	IR	94 (31)	NBP	64 (11)	78 (32)	100 (1)	80 (31)	NT	79 (29)	NT	IR	71 (21)
<i>Proteus mirabilis</i>	OPD	11	0 (4)	66 (6)	0 (3)	NT	IR	NT	NT	0 (3)	50 (2)	0 (9)	IR	NT
	IPD	8	50 (6)	57 (7)	50 (4)	60 (5)	IR	NT	67 (3)	0 (3)	100 (1)	100 (1)	IR	NT
	ICU	1	0 (1)	0 (1)	0(1)	0 (1)	IR	NT	NT	NT	NT	NT	IR	NT

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM PEDIATRIC DEPARTMENT JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM
ORTHOPEDICS DEPARTMENT
(JAN – DEC 2023)**

Antimicrobial susceptibility for gram positive pathogens from Orthopedic department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	No of isolates	Cefoxitin %(n)	Clindamycin %(n)	Erythromycin %(n)	Tetracycline %(n)	Chloramphenicol %(n)	Ciprofloxacin %(n)	Gentamicin %(n)	Trimethoprim/Sulfamethoxazole %(n)
<i>MRSA</i>	OPD	59	0 (50)	49 (57)	16 (56)	52 (14)	85 (28)	5 (19)	76 (25)	37 (8)
	IPD	68	0 (43)	50 (67)	23 (67)	43 (51)	74 (31)	4 (22)	67 (31)	50 (14)
<i>MSSA</i>	OPD	16	100 (16)	81 (16)	53 (15)	66 (15)	75 (4)	50 (4)	100 (6)	NT
	IPD	23	95 (21)	72 (22)	26 (23)	77 (18)	76 (13)	12 (8)	71 (7)	50 (2)
<i>Staphylococcus aureus</i>	OPD	100	24 (66)	57 (93)	26 (96)	60 (79)	87 (40)	13 (31)	80 (31)	68 (16)
	IPD	159	31 (66)	61 (115)	24 (157)	62 (103)	81 (71)	9 (75)	68 (41)	64 (28)
	ICU	1	NT	NT	0 (1)	NT	100 (1)	100 (1)	NT	NT
<i>Coagulase negative staphylococcus</i>	OPD	21	8 (12)	47 (19)	28 (21)	70 (17)	100 (8)	75 (4)	66 (6)	0 (2)
	IPD	19	0 (6)	40 (50)	31 (19)	78 (14)	60 (5)	33 (12)	40 (5)	60 (5)

Gram Positive Cocci	Location	No of isolates	Erythromycin %(n)	Linezolid %(n)	Tetracycline %(n)	Vancomycin %(n)	High level gentamicin %(n)	Chloramphenicol %(n)	Ciprofloxacin %(n)	Teicoplanin %(n)	Norfloxacin %(n)	Nitrofurantoin %(n)
<i>Enterococcus faecalis</i>	OPD	3	0 (1)	NT	NT	NT	NT	NT	NT	NT	NT	NT
	IPD	5	0 (2)	100 (1)	25 (4)	NT	66 (3)	100 (1)	0 (1)	66 (3)	0 (1)	0 (1)
<i>Enterococcus faecium</i>	OPD	1	NT	NT	0 (1)	100 (1)	100 (1)	NT	NT	NT	NT	NT
	IPD	4	0 (1)	100 (2)	0 (3)	100 (1)	25 (4)	NT	0 (1)	100 (2)	0 (2)	0 (3)
<i>Enterococcus spp.</i>	OPD	5	0 (1)	NT	NT	NT	NT	NT	NT	NT	NT	NT
	IPD	9	0 (3)	100 (3)	13 (7)	100 (1)	45 (7)	100 (1)	0 (2)	83 (5)	0 (3)	0 (4)
<i>Streptococcus spp.</i>	OPD	1	0 (1)	NT	100 (1)	NT	NBP	100 (1)	NBP	NBP	NBP	NBP
	IPD	5	20 (5)	NT	0 (2)	100 (4)	NBP	100 (1)	NBP	NBP	NBP	NBP


Antimicrobial susceptibility for gram negative pathogens from Orthopedic department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacteria	Location	No of isolates	Cefotaxime %(n)	Ceftriaxone%(n)	Amoxicillin/clavulanic acid%(n)	Piperacillin/tazobactam%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Meropenem%(n)	Tobramycin%(n)	Amikacin%(n)	Aztreonam%(n)	Ceftazidime%(n)	Chloramphenicol%(n)	Norfloxacin%(n)	Nitrofurantoin%(n)
<i>Escherichia coli</i>	OPD	10	33 (3)	0 (8)	100 (1)	16 (6)	0 (6)	25 (4)	12 (8)	0 (1)	50 (2)	33 (3)	50 (2)	0 (4)	0 (1)	NT	NT
	IPD	44	0 (1)	8 (36)	0 (1)	28 (28)	31 (19)	0 (16)	46 (41)	18 (16)	9 (11)	18 (16)	0 (2)	10 (10)	33 (3)	9 (11)	75 (12)
<i>Enterobacter spp.</i>	OPD	20	0 (1)	0 (16)	IR	0 (13)	21 (14)	0 (9)	13 (15)	50 (2)	14 (7)	0 (8)	0 (2)	0 (10)	0 (2)	NT	NT
	IPD	31	NT	7 (26)	IR	17 (23)	35 (20)	16 (18)	44 (27)	0 (2)	0 (8)	8 (12)	50 (8)	12 (8)	100 (4)	0 (4)	25 (4)
<i>Pseudomonas aeruginosa</i>	OPD	23	IR	IR	IR	85 (14)	NBP	41 (12)	73 (15)	NT	NT	100 (3)	60 (10)	61 (18)	IR	NT	IR
	IPD	26	IR	IR	IR	65 (20)	NBP	26 (15)	54 (22)	NT	NT	100 (1)	41 (12)	47 (19)	IR	66 (3)	IR
<i>Klebsiella spp.</i>	OPD	10	83 (4)	8 (7)	50 (4)	28 (8)	50 (5)	NT	0 (1)	25 (2)	50 (7)	8 (7)	0 (1)	25 (4)	NT	NT	NT
	IPD	44	9 (18)	32 (25)	3 (20)	24 (36)	17 (32)	NT	0 (1)	3 (20)	15 (37)	NT	0 (1)	20 (10)	25 (3)	25 (7)	25 (7)
	ICU	1	NT	NT	NT	0 (1)	0 (1)	NT	NT	0 (1)	NT	0 (1)	100 (1)	NT	NT	NT	NT
<i>Klebsiella pneumoniae</i>	OPD	8	NT	57 (7)	NT	0 (4)	16 (6)	50 (2)	50 (6)	NT	66 (3)	0 (3)	NT	50 (4)	NT	NT	NT
	IPD	39	0 (1)	15 (33)	NT	14 (27)	13 (23)	0 (22)	31 (35)	50 (2)	17 (17)	5 (18)	0 (2)	20 (10)	0 (1)	0 (5)	0 (5)
<i>Klebsiella oxytoca</i>	OPD	2	NT	0 (1)	100 (1)	0 (1)	100 (1)	NT	NT	NT	50 (2)	NT	NT	NT	NT	NT	NT
	IPD	5	0 (1)	50 (2)	0 (2)	33 (3)	20 (5)	NT	NT	0 (1)	0 (2)	NT	NT	NT	0 (1)	50 (2)	50 (2)
<i>Acinetobacter baumannii</i>	OPD	5	0 (1)	50 (2)	IR	33 (3)	20 (5)	NT	NT	0 (1)	0 (2)	NT	IR	NT	IR	NBP	NBP
	IPD	34	40 (10)	11 (15)	IR	17 (21)	0 (21)	NT	0 (2)	6 (18)	2 (25)	NT	IR	60 (11)	IR	NBP	NBP
	ICU	4	NT	NT	IR	0 (5)	0 (5)	NT	NT	0 (5)	0 (5)	NT	IR	NT	IR	NBP	NBP

Gram Negative Bacteria	Location	No of isolates	Cefotaxime %(n)	Ceftriaxone%(n)	Amoxicillin/clavulanic acid%(n)	Piperacillin/tazobactam%(n)	Gentamicin%(n)	Ciprofloxacin%(n)	Imipenem%(n)	Meropenem%(n)	Tobramycin%(n)	Amikacin%(n)	Aztreonam%(n)	Ceftazidime%(n)	Chloramphenicol%(n)	Norfloxacin%(n)
<i>Citrobacter spp</i>	OPD	13	0 (1)	25 (4)	0 (2)	7 (13)	21 (11)	NT	0 (1)	0 (9)	54 (11)	25 (6)	100 (1)	50 (2)	100 (1)	16 (8)
	IPD	27	0 (2)	13 (14)	0 (9)	47 (23)	61 (18)	NT	0 (2)	27 (22)	31 (28)	25 (4)	83 (4)	16 (11)	5 (2)	66 (3)
<i>Citrobacter koseri</i>	OPD	7	0 (1)	NT	0 (1)	14 (7)	42 (7)	NT	0 (1)	0 (6)	42 (7)	0 (4)	NT	50 (2)	100 (1)	NT
	IPD	15	NT	40 (10)	0 (5)	8 (13)	11 (9)	NT	0 (2)	0 (7)	27 (11)	0 (2)	100 (1)	0 (8)	50 (2)	0 (5)
<i>Citrobacter freundii</i>	OPD	6	NT	25 (4)	IR	0 (6)	0 (4)	NT	NT	0 (3)	25 (4)	50 (2)	100 (1)	NT	NT	NT
	IPD	10	NT	0 (2)	IR	25 (8)	16 (6)	NT	NT	50 (6)	28 (7)	50 (2)	50 (2)	33 (3)	NT	33 (3)
<i>Proteus mirabilis</i>	OPD	8	100 (1)	25 (4)	25 (4)	33 (6)	37 (8)	0 (1)	IR	12 (8)	NT	0 (1)	NT	100 (1)	NT	NT
	IPD	13	NT	66 (6)	33 (3)	44 (9)	90 (10)	0 (1)	IR	33 (6)	NT	41 (12)	100 (1)	50 (2)	100 (1)	0 (1)

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM ORTHOPEDICS DEPARTMENT JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM
OPHTHALMOLOGY DEPARTMENT
(JAN – DEC 2023)**

Antimicrobial susceptibility for gram positive pathogens from Ophthalmology department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]


Gram Positive Cocci	Location	Isolates	Erythromycin %(n)	Clindamycin %(n)	Tetracycline %(n)	Cotrimoxazole %(n)	Cefoxitin %(n)	Ciprofloxacin %(n)	Linezolid %(n)	Chloramphenicol %(n)
<i>S. aureus</i>	OPD	2	50 (2)	50 (2)	50 (2)	NT	50 (2)	NT	100 (1)	NT
	IPD	5	40 (5)	75(4)	80 (5)	NT	100 (3)	100 (1)	100 (2)	100 (1)
<i>CONS</i>	IPD	3	NT	NT	NT	NT	NT	0(2)	NT	NT
<i>S. pneumoniae</i>	OPD	1	100 (1)	100 (1)	0 (1)	100 (1)	NBP	NBP	NT	NT

Antimicrobial susceptibility for gram negative pathogens from Ophthalmology department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacilli	Location	Isolates	Ceftriaxone %(n)	Gentamycin %(n)	Ciprofloxacin %(n)	Piperacillin/tazobactam %(n)	Tobramycin %(n)	Imipenem %(n)	Ceftazidime %(n)
Pseudomonas aeruginosa	IPD	2	IR	NBP	NT	NT	100 (2)	100 (2)	0 (2)
Acinetobacter baumannii	IPD	1	0 (1)	0 (1)	0 (1)	0 (1)	NT	0 (1)	NT
Proteus mirabilis	IPD	1	100 (1)	100 (1)	0 (1)	NT	NT	IR	100 (1)

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM OPHTHALMOLOGY DEPARTMENT JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM ENT
DEPARTMENT
(JAN – DEC 2023)**

Antimicrobial susceptibility for gram positive pathogens from ENT department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]


Gram positive cocci	location	Isolates	Erythromycin %(n)	Clindamycin %(n)	Tetracycline %(n)	Cotrimoxazole %(n)	Cefoxitin %(n)	Ciprofloxacin %(n)	Gentamicin %(n)	Linezolid %(n)	High Level Gentamicin %(n)	Chloramphenicol %(n)
MRSA	OPD	77	9.2 (76)	57.1 (77)	49.2 (59)	50 (6)	0 (77)	16.7 (6)	40 (10)	100 (37)	NBP	83.3 (18)
	IPD	8	62.5 (8)	62.5 (8)	100 (6)	NT	0 (8)	NT	NT	100 (2)	NBP	100 (4)
MSSA	OPD	49	20.8 (48)	64.6 (48)	81.8 (33)	NT	100 (49)	0 (7)	62.5 (8)	100 (27)	NBP	80 (15)
	IPD	5	33.3 (3)	50 (4)	50 (2)	NT	100 (5)	NT	NT	NT	NBP	100 (1)
Staphylococcus aureus	OPD	197	15 (193)	62.1 (182)	63.4 (165)	75 (40)	34.5 (197)	55.1 (39)	50 (20)	100 (91)	NBP	88.6 (70)
	IPD	24	50 (22)	61.5 (13)	90 (10)	NT	36.4 (24)	10 (10)	NT	100 (12)	NBP	100 (11)
CONS	OPD	39	10.3 (39)	62.9 (85)	57.1 (28)	NT	12.5 (16)	11.1 (9)	80 (5)	93.3 (15)	NBP	100 (9)
	IPD	10	40 (10)	50 (4)	0 (2)	NT	100 (1)	14.3 (7)	100 (1)	100 (8)	NBP	100 (4)
Enterococcus spp.	OPD	3	0 (1)	IR	100 (1)	IR	IR	0 (2)	IR	0 (1)	100 (2)	100 (1)
	IPD	2	0 (1)	IR	0(2)	IR	IR	0 (1)	IR	100 (2)	50 (2)	NT

Antimicrobial susceptibility for gram negative pathogens from ENT department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacilli	Location	Isolates	Ceftriaxone %(n)	Gentamicin %(n)	Ciprofloxacin %(n)	Piperacillin/tazobactam %(n)	Amikacin %(n)	Tobramycin%(n)	Imipenem %(n)	Ceftazidime %(n)	Aztreonam %(n)	Norfloxacin %(n)
<i>Pseudomonas aeruginosa</i>	OPD	116	IR	NBP	46.6(88)	NT	100(1)	45.3(106)	73.4(109)	65.2(18)	73.2(49)	100(1)
	IPD	14	IR	NBP	10(10)	87.5(8)	NT	37.5(14)	70(10)	84.6(13)	57.1(14)	NT
<i>Proteus spp.</i>	OPD	29	58.3 (24)	45(20)	4.5(22)	56.7(27)	25(4)	0(1)	IR	100(2)	87.5(7)	NT
	IPD	4	66.7 (3)	0(1)	25(4)	66.7(3)	0(1)	NT	IR	NT	0(1)	NT
<i>Klebsiella pneumoniae</i>	OPD	18	58.3 (24)	36.4(11)	NT	56.7(27)	66.7(6)	100(2)	81.3(16)	100(2)	NT	33.3(9)
	IPD	6	60 (5)	0(3)	33.3(3)	0(4)	0(3)	0(1)	50(4)	NT	NT	NT
<i>Escherichia coli</i>	OPD	8	NT	NT	NT	83.3 (6)	NT	NT	NT	0(1)	NT	NT
	IPD	3	33.3 (3)	0(1)	0(2)	33.3(3)	0(1)	NT	50(2)	NT	NT	NT
<i>Citrobacter freundii</i>	OPD	9	37.5 (8)	67.7(9)	40(5)	25(8)	NT	NT	55.6(9)	0(2)	NT	NT
<i>Acinetobacter baumannii</i>	OPD	8	60 (5)	66.7(3)	50(6)	83.3(6)	100(2)	100(1)	75(8)	0(1)	IR	NBP
	IPD	1	NT	0(1)	0(1)	0(1)	NT	NT	0(1)	0(1)	IR	NBP

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM ENT DEPARTMENT JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM
DERMATOLOGY DEPARTMENT
(JAN – DEC 2022)**

Antimicrobial susceptibility for gram positive pathogens from Dermatology department


[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	Number	Cefoxitin %(n)	Cotrimoxazole %(n)	Clindamycin %(n)	Erythromycin %(n)	Linezolid %(n)	Vancomycin %(n)	Tetracycline %(n)	High level gentamicin %(n)	Chloramphenicol %(n)	Ciprofloxacin %(n)	Gentamicin %(n)	Teicoplanin %(n)
<i>MRSA</i>	OPD	23	0 (23)	50 (2)	65 (20)	30 (20)	100 (10)	NBP	67 (21)	NBP	100 (2)	0 (1)	67 (3)	NBP
	IPD	9	0 (9)	NT	33 (9)	22 (9)	NT	NBP	60 (5)	NBP	NT	0 (2)	100 (2)	NBP
<i>MSSA</i>	OPD	5	100 (5)	NT	100 (5)	60 (5)	100 (2)	NBP	67 (3)	NBP	100 (1)	0 (1)	100 (2)	NBP
	IPD	6	100 (6)	NT	50 (6)	33 (6)	100 (1)	NBP	0 (2)	NBP	0 (1)	0 (1)	NT	NBP
<i>Staphylococcus aureus</i>	OPD	59	22 (27)	54 (11)	74 (51)	32 (56)	100 (28)	NBP	68 (50)	NBP	100 (12)	20 (15)	80 (5)	NBP
	IPD	23	42 (12)	NT	42 (19)	26 (23)	89 (9)	NBP	44 (9)	NBP	86 (7)	11 (9)	100 (2)	NBP
<i>CONS</i>	OPD	20	25 (8)	NT	NT	79 (14)	100 (2)	NBP	NT	50 (12)	NT	NT	0 (4)	NBP
	IPD	9	0 (5)	NT	0 (1)	29 (7)	NT	NBP	NT	80 (5)	NT	NT	0 (1)	NBP
<i>Enterococcus faecalis</i>	OPD	3	IR	IR	IR	0 (1)	100 (1)	100 (1)	0 (2)	100 (3)	0 (1)	0 (1)	IR	100 (1)
<i>Enterococcus faecium</i>	OPD	1	IR	IR	IR	NT	100 (1)	NT	NT	100 (1)	NT	NT	IR	100 (1)
<i>Enterococcus spp.</i>	OPD	5	IR	IR	IR	20 (5)	40 (5)	NT	0 (5)	40 (5)	20 (5)	20 (5)	IR	40 (5)

Antimicrobial susceptibility for gram negative pathogens from Dermatology department

Gram Negative Bacilli	Location	Number of isolates	Piperacillin/tazobactam % (n)	Ceftazidime % (n)	Aztreonam % (n)	Imipenem % (n)	Gentamicin % (n)	Tobramycin % (n)	Ciprofloxacin % (n)	Norfloxacin % (n)	Nitrofurantoin % (n)	Ceftriaxone % (n)	Amikacin % (n)	Meropenem % (n)
<i>Escherichia coli</i>	OPD	19	50 (16)	67 (3)	NT	56 (16)	20 (10)	NT	0 (6)	36 (11)	73 (11)	21 (14)	100 (1)	NT
	IPD	13	0 (6)	NT	NT	17 (12)	0 (4)	0 (2)	0 (6)	0 (2)	100 (3)	0 (7)	NT	NT
<i>Enterobacter spp.</i>	OPD	12	41 (12)	0 (1)	100 (1)	70 (10)	90 (1)	NT	17 (6)	50 (4)	75 (4)	45 (11)	0 (1)	NT
	IPD	17	18 (11)	0 (4)	NT	25 (6)	33 (9)	0 (10)	12 (8)	0 (2)	50 (2)	8 (12)	0 (4)	0 (1)
<i>Pseudomonas aeruginosa</i>	OPD	4	100 (3)	100 (3)	100 (1)	100 (4)	NBP	0 (2)	66 (3)	NT	IR	IR	NT	NT
	IPD	12	40 (10)	33 (9)	42 (7)	55 (9)	NBP	50 (10)	100 (2)	NT	IR	IR	0 (1)	100 (1)
<i>Klebsiella pneumoniae</i>	OPD	5	25 (4)	NT	NT	100 (3)	0 (1)	100 (1)	0 (2)	0 (1)	0 (1)	25 (4)	0 (1)	0 (1)
	IPD	8	0 (2)	0 (1)	NT	14 (7)	20 (5)	50 (2)	NT	25 (4)	0 (4)	0 (3)	0 (3)	NT
<i>Citrobacter freundii</i>	OPD	4	100 (4)	NT	NT	75 (4)	33 (3)	NT	100 (1)	33 (3)	66 (3)	50 (4)	NT	NT
	IPD	3	0 (3)	0 (2)	NT	6 (2)	0 (2)	0 (1)	50 (2)	NT	NT	0 (1)	NT	NT
<i>Citrobacter koseri</i>	OPD	4	50 (2)	0 (1)	NT	50 (2)	0 (1)	NT	NT	0 (2)	100 (2)	33 (3)	NT	NT
<i>Citrobacter spp.</i>	OPD	8	50 (2)	NT	NT	0 (2)	NT	NT	0 (1)	0 (1)	0 (1)	0 (1)	0 (1)	NT
	IPD	4	0 (3)	NT	NT	25 (4)	NT	0 (1)	0 (3)	0 (1)	0 (1)	0 (3)	NT	NT
<i>Acinetobacter baumannii</i>	OPD	3	0 (3)	NT	IR	0 (3)	0 (2)	NT	33 (3)	NBP	NBP	0 (3)	NT	NT
	IPD	6	0 (3)	NT	IR	0 (6)	0 (1)	NT	0 (4)	NBP	NBP	0 (4)	0 (1)	NT
<i>Proteus mirabilis</i>	OPD	5	75 (4)	NT	66 (3)	IR	50 (2)	NT	0 (3)	NT	IR	75 (4)	0 (1)	NT
	IPD	1	100 (1)	100 (1)	NT	IR	100 (1)	NT	0 (1)	NT	IR	NT	NT	NT

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM DERMATOLOGY DEPARTMENT JAN – DEC 2023



**ANTIBIOTIC SUSCEPTIBILITY OF
PATHOGENS ISOLATED FROM
OBSTRETICS & GYNAECOLOGY
DEPARTMENT
(JAN – DEC 2023)**

Antimicrobial susceptibility for gram positive pathogens from Obstetrics & Gynaecology department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Positive Cocci	Location	Isolate	Cefoxitin %(n)	Cotrimoxazole %(n)	Erythromycin %(n)	Linezolid %(n)	Tetracycline %(n)	Clindamycin %(n)	Chloramphenicol %(n)	Ciprofloxacin %(n)	Gentamycin %(n)	Norfloracin %(n)	Nitrofurantoin %(n)
<i>MRSA</i>	OPD	39	0 (39)	17 (6)	20 (25)	100 (26)	46 (8)	31 (26)	100 (8)	0 (8)	50 (14)	0 (5)	89 (9)
	IPD	76	0 (76)	23 (13)	6 (72)	97 (30)	50 (42)	32 (72)	76 (21)	20 (20)	81 (16)	0 (2)	100 (2)
<i>MSSA</i>	OPD	17	100 (17)	NT	38 (8)	100 (11)	93 (15)	56 (9)	100 (2)	75 (4)	86 (7)	100 (1)	100 (6)
	IPD	31	100 (31)	40 (5)	49 (29)	93 (15)	42 (19)	69 (29)	100 (6)	40 (5)	100 (4)	NT	100 (1)
<i>Staphylococcus aureus</i>	OPD	83	29 (56)	44 (9)	21 (44)	98 (49)	57 (62)	38 (42)	87 (15)	18 (22)	60 (30)	13 (8)	88 (25)
	IPD	194	29 (107)	53 (32)	22 (183)	97 (102)	55 (105)	48 (156)	NT	22 (72)	82 (38)	20 (5)	100 (5)
<i>CONS</i>	OPD	26	27 (15)	NT	17 (12)	100 (9)	56 (16)	50 (14)	67 (6)	NT	50 (10)	0 (4)	100 (9)
	IPD	90	8 (37)	40 (10)	17 (79)	98 (54)	60 (58)	54 (68)	87 (23)	25 (24)	88 (17)	50 (2)	75 (4)

Gram Positive Cocci	Location	Isolate	Erythromycin %(n)	Linezolid %(n)	Vancomycin %(n)	Tetracycline %(n)	High Level Gentamicin %(n)	Ciprofloxacin %(n)	Teicoplanin %(n)	Norfloxacin %(n)	Nitrofurantoin %(n)
<i>Enterococcus faecalis</i>	OPD	36	NT	85 (13)	33 (3)	24(29)	68 (34)	25(12)	88 (25)	22 (12)	90 (21)
	IPD	77	0 (17)	78 (36)	67 (18)	15 (47)	61 (75)	18 (22)	93 (29)	8 (13)	63 (27)
<i>Enterococcus faecium</i>	OPD	9	NT	100 (4)	NT	0 (7)	100 (8)	0 (3)	86 (7)	20 (5)	60 (5)
	IPD	31	0 (12)	85 (20)	67 (6)	NT	33 (27)	8 (12)	77 (22)	0 (6)	50 (6)
<i>Enterococcus spp.</i>	OPD	47	NT	82 (33)	33 (3)	24 (30)	84 (42)	25 (15)	86 (32)	20 (17)	75 (28)
	IPD	194	22 (183)	97 (102)	NT	55 (105)	82 (38)	22 (72)	NT	20 (5)	100 (5)


Antimicrobial susceptibility for gram negative pathogens from Obstetrics & Gynaecology department

[% of susceptible (total number of isolates tested for a given antibiotic)=%(n)]

Gram Negative Bacilli	Location	Isolates	Amikacin %(n)	Gentamicin %(n)	Ceftriaxone %(n)	Piperacillin/tazobactam %(n)	Ceftazidime %(n)	Chloramphenicol %(n)	Ciprofloxacin %(n)	Imipenem %(n)	Tobramycin %(n)	Aztreonam %(n)	Meropenem %(n)	Norfloxacin %(n)	Nitrofurantoin %(n)
<i>Enterobacter spp.</i>	OPD	126	20 (15)	48 (79)	24 (86)	54 (100)	38 (8)	NT	9 (22)	78 (102)	50 (10)	0 (1)	NT	7 (79)	81 (97)
	IPD	219	37 (38)	49 (102)	16 (172)	40 (156)	4 (23)	71 (21)	13 (86)	56 (186)	27 (11)	17 (18)	50 (2)	31 (68)	79 (79)
<i>Escherichia coli</i>	OPD	163	45 (20)	63 (80)	29 (80)	58 (101)	39 (13)	79 (14)	5 (21)	78 (128)	39 (18)	0 (2)	100 (5)	34 (127)	85 (133)
	IPD	24	54 (28)	52 (134)	16(198)	43 (201)	28 (18)	84 (32)	9 (102)	68 (235)	39 (23)	27 (11)	100 (3)	30 (117)	79 (109)
<i>Klebsiella pneumoniae</i>	OPD	62	40 (10)	67 (30)	57 (28)	72 (36)	50 (8)	NT	13 (8)	75 (47)	50 (12)	NT	100 (3)	63 (40)	80 (50)
	IPD	154	36 (19)	43 (17)	19 (104)	43 (114)	11 (9)	77 (17)	18 (70)	52 (137)	59 (17)	20 (5)	86 (7)	44 (45)	48 (52)
<i>Klebsiella oxytoca</i>	OPD	14	50 (2)	67 (6)	17 (6)	25 (8)	0 (1)	NT	0 (3)	58 (12)	33 (3)	NT	NT	67 (6)	73 (11)
	IPD	33	56 (9)	47 (15)	17 (18)	32 (22)	0 (1)	100 (1)	11 (9)	41 (29)	0 (8)	NT	100 (1)	24 (17)	50(22)
<i>Klebsiella spp.</i>	OPD	76	50 (12)	67 (36)	57 (34)	49(44)	50(9)	100(1)	13(11)	67(59)	42(15)	20(5)	100(3)	65(46)	76(61)
	IPD	187	46(18)	45(23)	19(122)	37(126)	11(10)	100(1)	15(79)	46(166)	59(25)	20(5)	93(8)	34(62)	49(74)

Gram negative bacilli	location	Isolates	Amikacin % <i>(n)</i>	Gentamicin % <i>(n)</i>	Ceftriaxone % <i>(n)</i>	Piperacillin/tazobactam % <i>(n)</i>	Ceftazidime % <i>(n)</i>	Cefotaxime % <i>(n)</i>	Chloramphenicol % <i>(n)</i>	Ciprofloxacin % <i>(n)</i>	Imipenem % <i>(n)</i>	Tobramycin % <i>(n)</i>	Aztreonam % <i>(n)</i>	Norfloxacin % <i>(n)</i>	Nitrofurantoin % <i>(n)</i>
<i>Pseudomonas aeruginosa</i>	OPD	10	NT	NBP	IR	86 (7)	83 (6)	IR	IR	100 (3)	80 (10)	63 (8)	0 (6)	100 (3)	IR
	IPD	31	NT	NBP	IR	68 (19)	70 (20)	IR	IR	58 (12)	58 (24)	50 (26)	82 (11)	NT	IR
<i>Citrobacter freundii</i>	OPD	49	80 (5)	74 (23)	38 (24)	63 (35)	100 (3)	NT	NT	43 (7)	74 (35)	NT	NT	65 (26)	78 (32)
	IPD	62	0 (4)	33 (43)	16 (55)	29 (52)	0 (6)	NT	NT	11 (26)	50 (54)	20 (5)	29 (17)	14 (4)	56 (16)
<i>Citrobacter koseri</i>	OPD	65	0 (3)	54 (37)	33 (39)	66 (55)	50 (6)	50 (2)	50 (2)	8 (12)	80 (61)	NT	NT	41 (39)	67 (48)
	IPD	76	67 (9)	29 (35)	11 (66)	40 (60)	9 (11)	NT	44 (9)	11 (35)	48 (73)	0 (4)	0 (2)	48 (25)	71 (28)
<i>Citrobacter spp.</i>	OPD	126	80 (10)	50 (64)	38 (69)	69 (94)	61 (12)	50 (2)	50 (2)	43 (21)	80 (105)	33 (3)	NT	43 (73)	68 (85)
	IPD	173	67 (24)	36 (86)	26 (146)	40 (140)	50 (19)	60 (50)	44 (9)	12 (85)	50 (154)	40 (14)	50 (21)	48 (34)	80 (49)
<i>Proteus mirabilis</i>	OPD	4	50 (2)	0 (1)	50 (2)	67 (3)	NT	NT	NT	NT	IR	NT	NT	50 (2)	IR
	IPD	17	20 (5)	29 (7)	33 (12)	50 (14)	NT	NT	NT	11 (9)	IR	NT	NT	33 (3)	IR
	ICU	2	0 (1)	50 (2)	0 (2)	50 (2)	NT	NT	NT	50 (2)	IR	NT	NT	NT	IR
<i>Acinetobacter baumannii</i>	OPD	23	14 (7)	36 (14)	0 (16)	33 (18)	NT	NT	IR	10 (10)	43 (21)	NT	IR	NBP	20 (5)
	IPD	186	20 (25)	21 (100)	6 (139)	18 (128)	9 (21)	0 (3)	IR	15 (107)	13 (166)	17 (18)	IR	NBP	NT

ANTIBIOTIC SUSCEPTIBILITY OF PATHOGENS ISOLATED FROM OBSTRETICS & GYNAECOLOGY DEPARTMENT JAN – DEC 2023



CONTRIBUTORS

Dr. Shukla Das

Director professor & Head
Department of Microbiology
UCMS & GTB Hospital

Dr. Bineeta Kashyap

Director professor
Department of Microbiology
UCMS & GTB Hospital

Dr. Rumpa Saha

Director professor
Department of Microbiology
UCMS & GTB Hospital

Dr. Nisha Goyal

Associate professor
Department of Microbiology
UCMS & GTB Hospital

Dr. Charu Jain

Associate professor
Department of Microbiology
UCMS & GTB Hospital

Dr. Kirti Nirmal

Associate professor
Department of Microbiology
UCMS & GTB Hospital

Dr. Nadeem Ahmad

Associate professor
Department of Microbiology
UCMS & GTB Hospital

Dr. Manoj Kumar Meena

Associate professor
Department of Microbiology
UCMS & GTB Hospital

Dr. Subhashree Mohapatra

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. Dibyashree

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. Seema

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. S. Krishna Singha

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. Krishna Sarkar

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. Priyanka Gupta

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. Kapil Singh

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. Swati Nirmal

Senior resident
Department of Microbiology
UCMS & GTB Hospital

Dr. Sudeshna Das

Senior resident
Department of Microbiology
UCMS & GTB Hospital